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Adequate oxygen supply is vital for living tissues and cells. Today, oxygen satu-
ration measurement by pulse oximetry is a mandatory physiological parameter in
patient monitoring. It tells about the oxygen supply to tissues. In the presence
of elevated fractions of dyshemoglobins, pulse oximeters cannot measure oxygen
saturation of blood reliably. Accurate and instant diagnosis of dyshemoglobine-
mia, carbon monoxide poisoning, and acquired methemoglobinemia is difficult due
to nonspecific symptoms. Thus, in acute care blood samples must be taken for
ensuring adequate tissue oxygenation.
This thesis is a part of a project that aims to develop a novel, multi-wavelength
pulse oximeter that would provide a noninvasive and continuous total hemoglobin
and dyshemoglobin measurement. A prototype device that expanded the con-
ventional two wavelength system to eight wavelengths has been used to collect
development data from volunteer subjects for the algorithm development.
In this thesis the quality of the plethymosgraphic signals is compared to a com-
mercial pulse oximeter. Autocorrelation is used to evaluate the extra plethymos-
graphic signals. A fractional hemoglobin algorithm measuring oxyhemoglobin, car-
boxyhemoglobin, methemoglobin, and reduced hemoglobin fractions is developed.
The Beer-Lambert theory of non-scattering media is used to solve analyte fractions
after the in vivo measured signal are transformed to the corresponding non-scatter
signals using regression modeling. The algorithm is evaluated against clinically
relevant accuracy requirements, and validated using k-fold cross-validation.
The quality of the plethymosgraphic data turned out to be inadequate for the
fractional measurement of hemoglobins. Although the algorithm did not meet
the requirements, positive signs were seen, especially with methemoglobin mea-
surement performance. An improved prototype and more development data are
needed to prove the feasibility of the fractional hemoglobin algorithm.
Keywords: Beer-Lambert transformation, carboxyhemoglobin, continuous,
methemoglobin, multi-wavelength, non-invasive, plethymosgraphic
signal, pulse oximetry, regression modeling
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Riitta¨va¨ hapensaanti on elinta¨rkea¨a¨ kudosten ja solujen toiminnalle. Pulssioksi-
metria mittaa veren happisaturaatiota, joka kertoo osaltaan kudosten hapensaan-
nista. Se on nykya¨a¨n yksi pakollisista potilasmonitoroinnin mittauksista. Kor-
keat dyshemoglobiinipitoisuudet va¨a¨rista¨va¨t pulssioksimetrian arviota veren hap-
pisaturaatiosta. Yleisimpien dyshemoglobiinien, karboksi- ja methemoglobiinin,
kohonneiden pitoisuuksien luotettava diagnoosi on vaikeaa ilman verina¨ytteita¨,
koska niiden aiheuttamat oireet ovat epa¨spesifeja¨.
Ta¨ma¨ diplomityo¨ on osa projektia, jonka tarkoituksena on kehitta¨a¨ moniaallon-
pituuspulssioksimetri, joka mittaa dyshemoglobiiniosuudet ja kokonaishemoglobii-
nipitoisuuden ihoa vaurioittamatta. Projektin ensimma¨inen prototyyppilaitteisto
mittaa kahdeksaa plethymosgrafista signaalia normaalin kahden aallonpituuden si-
jaan. Laitteistolla kera¨ttiin vapaaehtoisilta koehenkilo¨ilta¨ tutkimusaineistoa, joka
kattaa laajan karboksi- ja methemoglobiinipitoisuusalueen.
Plethymosgrafisen tutkimusaineiston laatua analysoitiin vertaamalla sita¨ perin-
teiseen pulssioksimetriaan. Lisa¨ttyjen kanavien laadun tutkimiseen ka¨ytettiin au-
tokorrelaatiota. Ta¨ma¨n ja¨lkeen kehitettiin fraktionaalinen hemoglobiinialgoritmi,
joka laskee oksi-, karboksi-, met- ja deoksihemoglobiiniosuudet. Tyo¨ssa¨ ka¨ytettiin
regressiomallinnusta muuntamaan mitatut in vivo signaalit vastaamaan siroamat-
tomia Beerin ja Lambertin signaaleita, jolloin pitoisuudet voidaan ratkaista li-
neaarisesta yhta¨lo¨ryhma¨sta¨. Algoritmin suorituskykya¨ verrattiin kliinisiin tark-
kuusvaatimuksiin ja algoritmi validoitiin ka¨ytta¨ma¨lla¨ k-kertaista ristiinvalidointia.
Kera¨tyn tutkimusaineiston laatu osoittautui riitta¨ma¨tto¨ma¨ksi fraktionaaliseen
mittaukseen. Vaikkei algoritmi ta¨ytta¨nyt kliinisia¨ vaaatimuksia, lupaavia
merkkeja¨ erityisesti methemoglobiinin osalta oli havaittavissa. Uusi parannettu
prototyyppi pita¨a¨ kehitta¨a¨ ja lisa¨a¨ tutkimusaineistoa pita¨a¨ kera¨ta¨, jotta algorit-
min suorituskyky voidaan osoittaa riitta¨va¨ksi.
Avainsanat: Beer-Lambert–muunnos, fraktionaalinen, karboksihemoglobiini,
methemoglobiini, moniaallonpituus, noninvasiivinen, pulssioksime-
tria, plethymosgrafinen signaali, regressiomallinnus
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Symbols and abbreviations
Symbols
A absorbance
dA normalized differential absorbance
c concentration
ε extinction coefficient
I intensity
l path-length
λ wavelength
p partial pressure
t time
T temperature, transmission
Abbreviations
CO Carbon monoxide, cardiac output
CO2 Carbon dioxide
CTR Current transfer ratio
DC Direct current
fCTR Functional current transfer ratio
FFT Fast Fourier Transform
FLT Functional light transmission
FrOx Fractional pulse oximetry
Hb Hemoglobin
HbCO Carboxyhemoglobin
HbMet Methemoglobin
HbO2 Oxyhemoglobin, oxygenated hemoglobin
HbX hemoglobin fraction
LB Beer-Lambert
LED Light Emitting Diode
MSE Mean square error
O2 Oxygen
PCA Principal component analysis
PPG photoplethymosgraphic signal
R ratio-of-ratios
RHb Reduced hemoglobin, deoxygenated hemoglobin
RSD, SD (relative) standard deviation
SBIC Schwarz Bayesian Information Criteria
SaO2 Arterial oxygen saturation of blood
SpO2 Oxygen saturation measured by pulse oximetry
tHb total hemoglobin concentration
1 Introduction
Adequate oxygen supply is vital for living tissues and cells. In the absence of oxygen
supply cells will die and irreversible cell damage may occur in a few minutes. Low
blood oxygenation is extremely difficult to diagnose. Thus, continuous monitoring of
oxygen delivery is needed in healthcare. Today, oxygen saturation measurement by
pulse oximetry is a mandatory physiological parameter in patient monitoring. It is a
spectrophotometric measurement, plethymosgraphic signals of the pulsating blood
that gives an estimation of oxygen saturation of arterial blood. It was invented in
1975 by Takuo Aoyagi and commercialized in 1981 by the Biox company.
Pulse oximetry has its limitations. Conventional pulse oximeters are incapable
to measure oxygen delivery capacity of blood in the presence of dyshemoglobins
(carboxyhemoglobin or methemoglobin), or at low total hemoglobin concentration.
Carbon monoxide poisoning and methemoglobinemia often remain undetected before
dangerous levels, because of the common nature of the symptoms such as headache,
dizziness, and weakness. Carbon monoxide poisoning is a major cause of death by
poisoning in industrialized countries. Methemoglobinemia is more common than
thought and has been shown to cause morbidity and mortality. Anemia, low total
hemoglobin concentration, is the most common disorder in the blood.
Current laboratory methods to measure dyshemoglobinemia and total hemoglobin
concentration are invasive, time consuming, and discontinuous. Development of
novel multi-wavelength oximeters that would provide reliable noninvasive and con-
tinuous total hemoglobin and dyshemoglobin measurement, is driven by these lim-
itations. Diagnosis of anemia, carbon monoxide poisoning, or acquired methe-
moglobinemia with the non-invasive and continuous multi-wavelength oximeters
would improve patient safety and lower the cost of care. In 2005, one of the lead-
ing pulse oximeter manufacturers, Masimo Corporation, released a noninvasive and
continuous pulse oximeter for fractional hemoglobin measurement. In 2008, they
expanded it to measure total hemoglobin. Controversial results of the accuracy of
the devices have been reported.
This thesis is a part of project that aims for a non-invasive and continuous total
hemoglobin and dyshemoglobin measurement. The project started in 2008 with the
development of a prototype device. The conventional oximetry technology was ex-
tended from two to eight wavelengths. Development data was collected in 2009 and
2010 from volunteer subjects to cover different dyshemoglobin levels and changing
saturation range. The scope of this thesis is to analyze the plethymosgraphic data
acquired with the prototype, and to develop a robust and simple fractional pulse
oximetry (FrOx) algorithm that can reliably measure oxyhemoglobin, carboxyhe-
moglobin, methemoglobin, and reduced hemoglobin fractions.
Literature review of the theory of tissue oxygenation, pulse oximetry, and current
multi-wavelength solutions is conducted in chapter two. Chapter three reviews the
prototype development and clinical data collection phases of the project, and then
methods used in the data-analysis and algorithm development are explained. In
chapters four and five, the results are presented and discussed.
22 Background
Oxygen transport is vital for living organs, as oxygen is continuously needed for
metabolic reactions that release energy from nutrient molecules. Cells will die in
absence of oxygen supply. To understand how oxygen reaches cells, this chapter
first reviews how oxygen is transported to tissues through circulatory and respira-
tory systems. Then pulse oximetry as a common tool for blood oxygen saturation
measurement is reviewed. At the end a new approach to blood oxygenation mea-
surement, multi-wavelength pulse oximetry, is described.
2.1 Tissue oxygenation
Tissue oxygenation can be described as a multiple staged process where respiratory
and cardiovascular systems cooperate to supply oxygen (O2) and eliminate carbon
dioxide (CO2) in the body. In tissue oxygenation process presented in Figure 1,
respiratory system takes care of the gas exchange in the body (respiration) while
pulmonary and systemic circulation of cardiovascular system take care of oxygen
and carbon dioxide transportation in the blood.
Following sections explain in more detail how oxygen and carbon dioxide are ex-
changed and transported in the body. Then hypoxia, tissue oxygenation deficiency,
is reviewed.
Figure 1: Process of tissue oxygenation
32.1.1 Exchange of oxygen and carbon dioxide
In tissue oxygenation process (Fig. 1), pulmonary ventilation (breathing) moves
the ambient air in and out of the alveoli of the lungs through a series of cavities
and tubes of the respiratory system. Air flows between the atmosphere and the
lungs because of alternating pressure differences created by respiratory muscles.
The rate of ventilation is controlled by respiratory neurons which get feedback from
many mechanical and chemical receptors. For example rate of ventilation accelerates
during exercise due to increased carbon dioxide concentration in the blood. [1, 2]
The deoxygenated blood enters pulmonary circulation from the right heart. Ex-
ternal (pulmonary) respiration takes care of the diffusion of oxygen and carbon
dioxide between the alveoli and blood in pulmonary capillaries. Gases dissolve, dif-
fuse, and react according to their partial pressure, P , that is defined as the pressure
which the gas would have if it were the only gas present in the volume. Difference
in partial pressures between two regions initiates diffusion, the flow of gas molecules
from a region of higher partial pressure to a region of lower partial pressure. While
the inspired air in the alveoli has higher partial pressure of oxygen than in pulmonary
capillary, oxygen diffuses through alveolar-capillary membrane to the deoxygenated
blood until equilibrium of partial pressures is reached. At the same time carbon
dioxide diffuses to the opposite direction to reach the equilibrium. The rate of gas
exchange depends on the partial pressure difference, surface area, diffusion distance
and the solubility and molecular weight of the gases. [1]
After external respiration pulmonary circulation transports oxygenated blood to
the left heart from where it is pumped to the systemic circulation that covers all
body tissues. As the oxygen rich blood reaches systemic capillaries internal (tissue)
respiration takes care of the gas exchange between systemic capillaries and tissue
cells through interstitial fluid. Internal respiration does not occur before systemic
capillaries even if oxygenated blood passes oxygen depleted tissues because diffusion
distance is too big in bigger arteries [2]. As systemic tissue cells have about 5 mmHg
lower partial pressure of oxygen than oxygenated blood, oxygen diffuses into the
surrounding tissue. After internal respiration deoxygenated blood returns to the
right heart from where it is pumped to the pulmonary circulation and a new loop
begins. [1]
Oxygen dissociation curve shown in Figure 2 presents the oxygen saturation level
of hemoglobin as a function of partial pressure of oxygen (PO2) or in other words,
the affinity of oxygen to hemoglobin. The shape of the curve has physiological
advantages. The flat upper part means that despite relatively high changes in PO2
in external respiration the saturation level will be high. Normally PO2 of oxygenated
blood in systemic arteries is about 100 mmHg. The steep lower part means that
large amounts of oxygen can be released without a large drop in capillary PO2 during
internal respiration. PO2 of deoxygenated blood in systemic veins is about 40 mmHg.
During exercise or higher metabolic activity the partial pressure can decrease to
about 20 mmHg. [2, 3]
Many external factors either move the dissociation curve to the left (higher affin-
ity) where oxygen is more tightly bind to hemoglobin or to the right (lower affinity)
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Figure 2: Oxygen hemoglobin dissociation curve. Red dotted line describes the
situation where oxygen affinity is decreased and the green dotted line when the
oxygen affinity is increased. The typical partial pressures of deoxygenated and
oxygenated blood are marked with dotted vertical lines.
where oxygen is released more easily. These changes are illustrated in Figure 2
with green and red dotted lines. Increasing acidity (decreasing pH) moves the curve
to the right because increased amount of hydrogen ions alters the structure of the
hemoglobin molecule and its oxygen-carrying capacity decreases. Same effect occurs
when partial pressure of carbon dioxide increases and more hydrogen ions are avail-
able in the blood. In addition, increasing temperature and 2,3-bisphosphoglycerate
(DPG) concentration, break down product of glycolysis, help unloading of oxygen
from hemoglobin and the curve moves to the right. Increase in concentrations of
dyshemoglobins moves the curve to the left. [1, 3]
2.1.2 Transport of oxygen and carbon dioxide in the blood
Oxygen and carbon dioxide are transported in the blood with different ways. Oxygen
is transported either in dissolved state or in chemical combination with hemoglobin
in the red blood cells. Only about 1.5 percent of oxygen is dissolved in blood plasma
and the rest is bound to the hemoglobin molecule.
Figure 3 presents the structure of the hemoglobin molecule. The quaternary
structure of hemoglobin consists of globin, a protein composed of two alpha and
two beta polypeptide chains and four nonprotein pigments called hemes. A heme
contains an iron atom that is normally in the ferrous (Fe2+) oxidation state to
5support oxygen binding. The change in the shape of the quaternary structure with
level of oxygenation alters the optical absorption spectrum. [1, 3]
Figure 3: Iron-containing heme, hemoglobin molecule and red blood cell [4].
Oxygen and hemoglobin combine in an easily reversible reaction written in Equa-
tion 1 to form oxyhemoglobin (HbO2). After first oxygen molecule binds to heme of
the hemoglobin molecule it is easier for other oxygen molecules to bind to the other
hemes. This is true also for the reverse reaction. [3]
RHb + O2 ←→ HbO2
Reduced hemoglobin Oxygen Oxyhemoglobin
(1)
Hemoglobin has some competitive binding of other compounds than oxygen in-
cluding carbon monoxide, cyanide, sulfur monoxide, nitrogen dioxide and sulfide. All
of these bind to the iron in the heme inhibiting oxygen-binding. Also change in the
oxidation to ferric (Fe3+) state converts hemoglobin into methemoglobin (HbMet),
which cannot bind oxygen. [1]
Carbon dioxide is transported in the blood in three ways: about seven percent
is dissolved in blood plasma, 23 percent is combined with globin forming products
called carbamino compounds, and the rest as bicarbonate ions within red blood
cells. [1]
2.1.3 Hypoxia
Hypoxia, cellular oxygen deficiency, occurs when oxygen demand in tissues exceeds
oxygen delivery. Tissue oxygen delivery is defined as described in Equation 2. Car-
diac output (CO) is the amount of blood flow in the cardiovascular system, total
hemoglobin concentration (tHb) is a measure of oxygen carrying capacity of the
blood and arterial oxygen saturation (SaO2) is the relative amount of oxygenated
hemoglobin.
DO2 (g/min) = CO (L/min) · tHb (g/L) · SaO2 (%)
Oxygen delivery cardiac output hemoglobin oxygen
concentration saturation
(2)
Possible symptoms of hypoxia include severe headaches, cyanosis (a bluish dis-
coloration of the skin and mucous membranes), nausea, hyperventilation, fatigue,
6seizures, coma, and death. The symptoms vary depending on the severity of the
hypoxia. Prolonged gradually developing hypoxia is difficult to recognize. Extreme
hypoxia, anoxia, is complete deprivation of oxygen supply to the tissues. In presence
of anoxia, especially some organs with high metabolic rate may suffer irreversible
damages. For example cerebral cortex survives for less than one minute, heart for five
minutes, liver and kidney for ten minutes and skeletal muscles for two hours. [2,3,5]
Hypoxia is classified in four groups based on the cause: hypoxic, anemic, is-
chemic or histotoxic hypoxia. In hypoxic hypoxia,oxygen concentration of arterial
blood is low due to low partial pressure of oxygen in arterial blood caused by res-
piratory disease or low fraction of inspired oxygen. In anemic hypoxia, the amount
of functional hemoglobin is reduced for example because of elevated dyshemoglobin
or anemia. In ischemic hypoxia, blood flow is very low affecting the rate of oxygen
delivery. In histotoxic hypoxia, some toxic agent prevents tissues to use oxygen even
in otherwise sufficient supplies of oxygen.
Hypoxemia is defined as low oxygen saturation in blood and does not neces-
sarily cause hypoxia if the demand of oxygen does not exceed oxygen delivery. In
this section, causes of hypoxemia, carboxyhemoglobinemia, methemoglobinemia and
anemia are further reviewed. [1, 2]
Carboxyhemoglobinemia
Carbon monoxide (CO) poisoning or carboxyhemoglobinemia is a leading cause of
death by poisoning in developed countries. CO is colorless, odorless and poisonous
gas that binds to hemoglobin forming carboxyhemoglobin (HbCO). Carbon monox-
ide’s affinity to bind to hemoglobin is 200–250 times greater than oxygen’s. Carbon
monoxide decreases the oxygen carrying capacity of hemoglobin and increasing con-
centration of HbCO decreases the oxygen release from hemoglobin to tissues. CO
poisoning is caused by inhalation of carbon monoxide, tobacco smoking, fumes,
faulty heating systems, automobiles, charcoal burners and fires. Nonsmokers have
normal carboxyhemoglobin levels from one to three percent whereas smokers may
have level up to fifteen percent. [6]
Symptoms of carboxyhemoglobinemia are similar with conditions such as flu,
viral infections, migraine and food poisoning. Common nature of symptoms can be
seen from Table 1 which lists the acute symptoms reported by patients after carbon
monoxide exposure. Only weak correlation has been shown between the HbCO level
and the severity of the symptoms. Skin decoloration to cherry pink is seldom seen
in living patients although it is the classical feature of CO poisoning [7]. Delayed
symptoms can occur after many days or even months after poisoning. These include
myocardial injury and development of neurophysiological syndrome with symptoms
such as behavioral changes, parkinsonism and dementia. Because CO poisoning can
result in long-term morbidity even if treated, prevention, diagnosis and treatment are
extremely important. CO exposure for more than one hour may increase morbidity.
Especially very young and old people are at greater risk. [6, 8, 9]
Yearly about 2800 people die unintentionally for CO poisoning in the United
States from which non-fire related deaths account for approximately 500 [8, 10].
7Table 1: Symptoms reported by patients after exposure to carbon dioxide.
Symptom Percentage of patients
Headache 91
Dizziness 77
Weakness 53
Nausea 47
Confusion 43
Shortness of breath 40
Visual changes 25
Hampson and Weaver estimated that there are approximately 50 000 emergency
department visit for CO poisoning corresponding to a prevalence of 1 to 10 000 in
a population in the United States every year. The count was significantly higher
than previous estimations (10 000 to 15 000). [11] In Great Britain the death rate
was 250 but there is a concern that figures are greater [9].
When diagnosis of carboxyhemoglobinemia is established the patient needs to be
removed from the source and then treated with high flow of normobaric or hyperbaric
oxygen (HBO) as soon as possible. In HBO, patients are exposed to high partial
pressure of oxygen. Carbon monoxide has half-life of four to six hours in room air,
40 to 80 minutes in normobaric 100 % oxygen and 15 to 30 minutes in HBO. Some
contradictory results of the benefit of HBO have been reported and the treatment
includes risks. [6, 7, 9]
Methemoglobinemia
Methemoglobin is formed when ferrous iron (Fe2+) is oxidized to ferric state (Fe3+)
which is unable to carry oxygen. Normal methemoglobin level in the blood is
from zero to two percent. Several endogenous reduction systems exist to maintain
hemoglobin in ferrous state. During methemoglobinemia oxygen carrying capacity
is reduced for two reasons: maximum oxygen carrying capacity is lowered and any
oxygen that is carried by a deoxidized hemoglobin subunit is held on to more tightly
and poorly released to tissues. Also ferric iron has greater affinity for monovalent
anions (CN−, F− and Cl−) compared to uncharged binding compounds (CO2, CO
and O2). [12]
Some common drugs including dapsone and local anesthetic agents such as ben-
zocaine and lidocaine, a variety of nitrogen containing chemicals, dyes, fertilizers and
industrial products cause methemoglobinemia. Some of these oxidize hemoglobin di-
rectly and some by reducing oxygen to free radical O−2 . Methemoglobinemia is also
induced if protective reduction systems are inhibited. Genetic defects in red blood
cell metabolism or hemoglobin structure also cause methemoglobinemia. [12, 13]
8Diagnosing methemoglobinemia is extremely difficult. It is asymptomatic up
to concentrations of 10− 15 % and even with higher concentrations symptoms are
similar with general disorders like cold, flu and viral infections. With higher than
10 % concentration color of blood may turn to chocolate brown. Table 2 shows the
symptoms and signs associated with different methemoglobin levels. [3, 14] Rapid
changes may induce severe symptoms with when lifelong methemoglobinemia can
be asymptomatic with same levels [13]. Few studies show that clinical factors such
as sepsis, anemia, hospitalization are associated to acquired methemoglobinemia
[15–17].
Table 2: Symptoms and signs of methemoglobinemia
%MetHb Symptoms or signs
0–15 asymptomatic
15–20 chocolate brown blood, clinical cyanosis
20–45 dyspnoe; fatigue, dizziness, lethargy, headache, syncope
45–55 decreasing level of consciousness
55–70 come, convulsions, cardiovascular failure, cardiac arrhytmias
> 70 death
In 2004, Ash-Bernal et al. published retrospective analysis that proved that
acquired methemoglobinemia (> 2 %) is more common than thought. They collected
CO-oximetry data for 28 months and found that 414 (19 %) of 2167 patients had
elevated methemoglobin levels. During the study acquired methemoglobinemia let
to one death and three near-deaths. In this study, dapsone was the most common
etiology of acquired methemoglobinemia. [15]
Moore et al. [18] reported that in cases where benzocaine products were used,
67 % of cases involved either definite or probable acquired methemoglobinemia.
In addition, Guay [19] summarized all episodes of local anesthetic-related methe-
moglobinemias found from literature. Based on the study they concluded that ben-
zocaine should not be used anymore and use of prilocaine should be avoided with
under 6-year old children, pregnant women or with patients taking other oxidizing
drugs.
The treatment of methemoglobinemia should include both symptomatic and spe-
cific therapy. Symptomatic treatment ensures oxygen supply and maximizes the
oxygen carrying capacity of hemoglobin. Most common specific treatment is infu-
sion of methylene blue. Also ascorbic acids are given for some patients. In all cases,
aggressiveness and type of treatment needs to be determined case by case keeping
symptoms and other conditions in mind. [13, 14, 19]
Anemia
Anemia is the most common disorder in the blood. In anemia, the oxygen-carrying
capacity of blood is reduced because of reduced number of red blood cells or de-
creased amount of hemoglobin in the blood. Iron-deficiency, impaired red blood cell
9production, increased red blood cell destruction, blood loss and fluid overload are
common causes of anemia. [1]
Medically anemia is defined as hemoglobin concentration (tHb) under 120 g/L
for females and under 130 g/L for males. Generally anemia is thought to be a
minor medical condition although healthcare professionals have stated that it affects
negatively to mortality and morbidity. Worldwide it is estimated that over two
billion people are affected by anemia. [20]
Symptoms of anemia include weakness, fatigue, poor concentration, coldness and
skin paleness. In addition, it is associated with other diseases such as cancer, HIV
and rheumatoid arthritis. WHO has stated that anemia is the largest global illness
adversely affecting mortality and worker capacity. Especially in developing countries
these effects of anemia are amplified. [1, 20, 21]
Treatment of anemia depends on the severity or the cause. Iron-deficiency ane-
mia is easy treat with iron supplements. Medicines that stimulate red blood cell
production can be used with chronic anemia. Acute anemia or cases with ongoing
blood loss can be treated with blood transfusion. [1]
2.2 Pulse oximetry
Pulse oximetry is a relatively recent essential tool in current practice of medicine
both in care of anaesthesia and critical care that measures blood oxygenation. Cur-
rent two wavelength pulse oximetry is based on two principles: distinction of arterial
blood pulsation from the other tissue components, and different absorption spectra
of oxyhemoglobin (HbO2) and reduced hemoglobin (RHb) over wavelengths.
Conventional pulse oximeters show plethymosgraphic signal and SpO2 value that
is defined as arterial oxygen saturation measured by pulse oximetry. Plethymos-
graphic signal presented in Figure 4 is the transmission signal of alternating arterial
blood component that is normalized with constant component reflecting the absorp-
tion of static arterial blood component, venous blood and other tissues such as skin,
pigmentation and bones. The transmission of light decreases during systole and
increases during diastole. [3]
Systole
Dicrotic notch
Diastole
99
%SpO2
BPM
72
Figure 4: A typical view of pulse oximeter screen. In addition to SpO2 value,
plethymosgraphic signal and pulse rate are shown.
Plethymosgraphic signal is normally used to recognize unreliable SpO2 mea-
surement but it can also be used in detecting and diagnosing cardiac arrhythmias,
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measuring vascular distensibility and determination of systolic blood pressure. Stan-
dardization and quantification of the plethymosgraph needs still to be clarified before
the clinical potential of plethymosgraphic signal is revealed. In addition to SpO2
measurement and plethymosgraph modern pulse oximeters provide some other in-
formation, such as pulse rate (PR), perfusion index (PI), a measure of relative
strength of perfusion, and pleth variability index (PVI), a measure of fluid respon-
siveness. [3, 22, 23]
This section describes how blood oxygenation can be measured by pulse oximetry.
First the basis of oximetry, Beer-Lambert law, is explained, then the theory of pulse
oximetry and calibration methods are described. At the end accuracy and limitations
of pulse oximetry are reviewed.
2.2.1 Beer-Lambert law in oximetry
The measurement principle of oximetry is based on Beer-Lambert law presented
in Figure 5 that describes light attenuation through a sample of homogenous non-
scattering media.
Distance (d)
Light intensity
l
Incident light Transmitted light
I(d) = I0e
−ελc · (d−a)
I
I0
a a+ l
Figure 5: Beer-Lambert law
Mathematically law is expressed as
I = I0e
−ελcl, (3)
where I is the transmitted intensity of the light, I0 is the incident intensity, ελ
is the extinction coefficient or absorptivity of the absorbent at wavelength λ, c is
the concentration of the absorbent, and l the optical path-length of the sample.
Beer-Lambert law is valid when there is one unknown substance in clear, non-turbid
solution and constant path-length. In addition, there should be no chemical reac-
tions or reactions between absorbent and solvent.
In case where the sample consists of layers of absorbents as presented in Fig-
ure 6, the total intensity of transmitted light presented in Equation 4 is a linear
superposition of intensities of each absorbent
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a1 a2 a3
Incident light, I0 Transmitted light, I
Figure 6: Layers of absorbents in a sample in Beer-Lambert situation.
I = I0e
∑
−ελ,acala = I0e
−A, (4)
where a represents an absorbent or analyte. [2, 3]
Oximetry is based on the change in the absorption of electromagnetic energy
(color) of hemoglobin molecule when its chemical binding is altered. Oxyhemoglobin,
reduced hemoglobin, carboxyhemoglobin and methemoglobin have their own char-
acteristic colors that can be described with extinction coefficients. The extinction
coefficients of four most common hemoglobin species are presented in Figure 7 in
the wavelength range from 570 to 1000 nm the visible light end of the spectrum into
the near infrared. Figure shows that HbCO is not absorbing almost at all at long
wavelength and has quite similar absorption with oxyhemoglobin with short wave-
lengths. Methemoglobin absorbs heavily around 640 nm and wavelengths above
840 nm. Wavelengths most commonly used in pulse oximetry 660 nm (red) and
940 nm (infrared) are marked with vertical lines. Their selection is based on large
difference in absorptions of HbO2 and RHb, manageable tissue absorption and flat-
ness of spectrum. [2, 3]
600 650 700 750 800 850 900 950 1000
10−2
10−1
100
101
Ex
tin
ct
io
n 
co
ef
f (1
/(m
mo
l/l)
/cm
)
Wavelength (nm)
660nm 940nm
RHb
HbO2
HbCO
HbMet
Figure 7: Extinction coefficients of hemoglobin species in the range from 570 to
1000 nm.
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2.2.2 Theory of pulse oximetry
Absorbance (A) at wavelength λ is defined as the negative natural logarithm of the
fraction of light that passes through a sample called transmission T . Combined with
Equation 4 the absorbance can be written in form
Aλ = −ln(T ) = −ln
(
I
I0
)
=
∑
a
ελ,a · ca · la, (5)
where a represents all tissue components such as arterial blood, venous blood,
skin and bones in the sample.
Figure 8 presents the how the photoplethymosgraphic (PPG) signal is formed.
The lower part presents the tissue layers in a sample and upper part shows the trans-
mission signal. DC component of transmission signal is defined as the transmission
without blood volume pulsation. DC component varies only slowly due to respira-
tion, sympathetic nervous system activity, thermoregulation and changes in total
hemoglobin concentration. In pulse oximeters, the time-dependent arterial pulsa-
tion of transmission signal, also called AC component, is separated from the total
transmission signal. The strength of the AC component is only about one to two
percent of the total transmission. It is the time-derivative of the total absorbance
where the only time-dependent signal is the path length, lart, through arterial blood.
Differential absorption (dAλ) is presented in equation
dAλ =
d(Aλ)
dt
·∆t = dlart
dt
·
∑
ελ,art · cart ·∆t. (6)
On the other hand differential absorption can be assessed through transmitted
intensity (Eq. 5) through the arterial blood component as written in equation
dAλ =
d
(
−ln
(
I(t)
I0
))
dt
·∆t = I
′
(t)
I(t)
·∆t ∼= ACλ
DCλ
=
Imax − Imin
Imax
. (7)
During one pulse differential absorption can be approximated with the DC com-
ponent (DCλ) and AC component (ACλ) intensities, that can be calculated from the
minimum transmission after systolic rise, Imin, and diastolic maximum transmission
of light, Imax.
Current conventional two wavelength pulse oximeters use light-emitting diodes
(LEDs) of wavelengths 660 nm (red light) and 940 nm (near-infrared light) and
semiconductor photodetector to obtain plethymosgraphic signal from an extremity
such as finger or earlobe. Ratio of two differential absorptions with different wave-
lengths, ratio-of-ratios (R), is calculated to obtain SpO2. Based on theory, R can
be presented with equation
R =
dAred
dAired
=
(εHbO2,red · cHbO2 + εRHb,red · cRHb) ·∆l
(εHbO2,ired · cHbO2 + εRHb,ired · cRHb) ·∆l
. (8)
When the thickness of the heartbeat-added arterial layer, ∆l, is estimated to
be equal for both wavelengths, assumption, tHb ·SpO2 ≈ cHbO2, is made, and a
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Figure 8: Light transmission during plethymosgraphic measurement.
constraint of two hemoglobin species, cRHb + cHbO2 = tHb, is included, the
equation can be rewritten in form
R =
εHbO2,red ·SpO2 + εRHb,red · (1− SpO2)
εHbO2,ired ·SpO2 + εRHb,ired · (1− SpO2)
, (9)
which can be solved for SpO2 as presented in equation
SpO2 = −
εRHb,red −R · εRHb,ired
(εHbO2,red − εRHb,red)−R · (εHbO2,ired − εRHb,ired)
. (10)
Theory presented above is based on the Beer-Lambert assumptions that in reality
are not valid in in vivo tissues. Other substances are present in blood and the
incident light is partially scattered, refracted and reflected. The detected light at
the photodetector consists of photons that travel different routes. Some of the
photons travel through the tissue without migrating from the line that emitter and
detector form and some scatter farther from the line and still reach the detector at
the other end. When the absorption increases the detected light tends to come more
from the shorter paths. Because of this path lengths vary with different wavelengths.
Because of these deviations from the Beer-Lambert law conventional pulse oximeters
are empirically calibrated to give better estimation of oxygen saturation. [2, 24]
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2.2.3 Calibration
Pulse oximeters are calibrated to compensate deviations from Beer-Lambert law.
They can be calibrated either against functional or fractional oxygen saturation of
arterial blood. [3, 25] Functional saturation is defined as shown in equation:
Functional SaO2 =
cHbO2
cHbO2 + cRHb
× 100%. (11)
Using this definition oxygen saturation can reach 100 % even in the presense of
other ligands such as HbCO. Many manufacturers use functional calibration in their
devices. Dyshemoglobins, carboxyhemoglobin and methemoglobin, are included in
the definition of fractional saturation presented in equation:
Fractional SaO2 =
cHbO2
cHbO2 + cRHb + cHbCO + cHbMet
× 100%. (12)
Calibration procedure of pulse oximeters is presented in Figure 10. Test subjects
are volunteers that range in age, gender and skin tone. For example U.S. Food
and Drug Administration (FDA) requires that at least 30 % of volunteers need to
have dark skin pigmentation. Calibration of pulse oximeters assumes normal dyshe-
moglobin level that is ensured with pre-screening blood test before data collection.
Normal methemoglobin level is about 0.4 % and carboxyhemoglobin level of 1− 3 %.
In test subject preparation, arterial cannula is set for drawing arterial blood
samples. Blood circulation of fingers is checked after cannulation. Measurement
sensors are attached to the extremities of the test subject. Before data collection
starts 100 % saturation level is ensured by letting the subject breath an oxygen/air
mix. [2, 26]
During data collection oxygen content of the blood is reduced incrementally by
letting the subject breath gas mixtures with low oxygen content. Blood samples
are taken at each level when the pulse oximeter shows stable reading and they are
analyzed with CO-oximeters. Samples are collected at least over saturation range
from 70 % to 100 %. With in vivo calibration method only saturation levels down
to 60 % can be reached due to ethical issues. Values below 60 % can be achieved
through in vitro calibration using blood. [2, 27]
In calibration curve of pulse oximeters either functional or fractional saturation
is plotted against measured ratio-of-ratios. A best fit curve is fitted to the collected
data using regression methods. The data is stored in form of look-up table of
calibration equation in the pulse oximeter. An example of a calibration plot is
shown in Figure 9. [2]
Pulse oximeter performance against requirements of authorities needs to be ver-
ified before they can reach the market. For example FDA recommends the use of
standard ISO 9919 that was recently revised with ISO 80601-2-61 Medical electrical
equipment – Part 2-61: Particular requirements for basic safety and essential perfor-
mance of pulse oximeter equipment. It requires that manufacturers need to report
the calibration range, reference, accuracy, methods of calibration and range of dis-
played saturation level. In addition, FDA recommends that at least 200 data points
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Figure 9: An example of a calibration data set and a best fit calibration curve.
Test subject selection
Test subject preparation
Data collection
Calibration calculation and storing
Figure 10: Calibration procedure of pulse oximeters.
equally spaced over a saturation range of 70 to 100 % are collected and accuracy
(ARMS) is at least 3− 3.5 %. [2, 26, 27]
In calibration process, blood samples are analyzed with CO-oximeters. CO-
oximetry or hemoximetry is the ’gold standard’ of blood oxygenation measurements.
CO-oximetry is invasive and non-continuous measurement designed to measure total
hemoglobin and hemoglobin species. In CO-oximeters small samples of blood are
hemolyzed to reduce the amount of scattering and passed into to a cuvette with
known path-length. Commercially available devices use at least four wavelengths to
be able to measure all four relevant forms of hemoglobin. Wavelengths are selected
normally from the range under 700 nm. [2, 3]
All errors in CO-oximetry readings are carried into the pulse oximeters in the
calibration phase. Any scattering substances left in the cuvette such as lipids or cell
fragments produce an error in the reading. The CO-oximetry accuracy of fractional
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oxygen saturation is about 0− 1 % with high saturation (≥ 97 %) and error increases
with lower saturation levels. Methemoglobin accuracy was estimated to be about
0− 1 % and carboxyhemoglobin 0− 4 %. [27,28]
In addition to inconvenience of the CO-oximetry measurement due to invasive
blood samples, other disadvantages are discontinuity and the cost of the measure-
ment. Hampson et al. [29] reported that fewer than half-of acute care hospitals
had the capability to measure dyshemoglobin. Others have to send the samples to
an another hospital. Anyway CO-oximetry is one of the most accurate methods
for measuring all four species of hemoglobin and it is used as the standard against
which other methods are compared. [2, 3]
2.2.4 Accuracy and limitations of pulse oximetry
Several factors affect the accuracy of pulse oximetry reading. In pulse oximetry,
SpO2 values are compared to CO-oximetry results. Commonly reported parame-
ters are bias, precision and accuracy root mean square (ARMS). Bias is defined
as the mean of differences between pulse oximeter value and CO-oximeter value as
presented in equation
bias =
∑N
i (SpO2i − SaO2COox,i)
N
= x, (13)
where SaO2COox,i is the CO-oximeter value, SpO2i is the saturation measured
by pulse oximetry and N is the number of measurements in a specified oxygen
saturation range. Positive bias means that pulse oximeter overestimates the actual
saturation. Precision is the standard deviation of the data cloud around the best fit
line as presented in equation
precision =
√∑N
i (SpO2i − SpO2mean,i)2
N − 1 , (14)
where SpO2mean,i is the value of the best fit curve. Precision tells how big the
data cloud is, not how far from the correct value the values are. Accuracy root
mean square (ARMS) is the root mean square error of the pulse oximeter value and
CO-oximeter value. ARMS is the value that is required by regulatory agencies when
overall quality of the device is evaluated. [2, 27] It is calculated with equation,
ARMS =
√∑N
i (SpO2i − SaO2COox,i)2
N
. (15)
In healthy volunteers, oximeters have been reported to have less than two percent
bias and less than three percent precision when SaO2 is above 90 %. The accuracy
differs between manufacturers mainly due to different signal processing techniques.
Accuracy deteriorates when SaO2 decreases. [30, 31]
Various limitations of pulse oximetry affect its accuracy. They arise from differ-
ent sources and can be divided in two categories, technical and physiological limita-
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tions. Some of them can be avoided with pulse oximeter design or signal processing
techniques. Table 3 lists the most common limitations of pulse oximetry. [2, 3]
Table 3: Limitations of pulse oximetry
Technical Physiological
Ambient light Dyshemoglobins
Optical shunt Other absorbents
Motion artifacts Low perfusion
Calibration Venous pulsations
Malpositioning of the sensor Pigmentation
As pulse oximeters only have two wavelengths, they can measure only two sub-
stances. Other substances (false absorbers) in the blood or on the tissue such as
HbCO or HbMet interfere spectrally with pulse oximetry. The effects of HbCO
and HbMet on pulse oximetry are presented in Figure 11. In presence of elevated
HbCO, pulse oximeters overestimate SaO2 values approximately with the percentage
of HbCO in the blood [32, 33]. With elevating methemoglobin level, SpO2 reading
initially decreases but not as steeply as SaO2. With HbMet level at 30− 35 % %
SpO2 level stabilizes to a level of 82− 86 % because HbMet adds to both signals
when ratio-of-ratios drives towards unity. [34]
Figure 11: The effects of carboxyhemoglobin [32] and methemoglobin [34] on pulse
oximetry readings. Black squares represent SaO2 (O2Hb) values and unfilled squares
on the left and black circles on the right represent SpO2 values.
Reynolds et al. [35] calculated the effects of elevated dyshemoglobin levels theo-
retically and compared them to in vitro test results. They noticed that the theo-
retical relationships based on a pure absorbing solution are not easily applicable to
a clinical situation but give a good approximation of the effects.
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Intravenous dyes such as methylene blue, indocyanine green and indigo carmine
can be a reason for falsely low SpO2 readings. For example methylene blue has
very high absorbance at 660 nm. In contrary, hyperbilirubinemia does not affect
the accuracy, even though it might cause artifactual high HbCO and HbMet levels
measured by CO-oximetry. Other possible sources of errors are black, green and
blue nail polishes. Fetal hemoglobin and sickling red blood cells have been reported
not to have significant effects on pulse oximetry. Controversy reports have been
reported from the effect of anemia, some of them claim that underestimation of
SaO2 occurs at low hemoglobin concentrations and some that anemia has no effect
on SpO2. [3, 30]
Triscupid incompetence with regurgitation, arteriovenous dissociation, right heart
block and right atrial myxoma might cause pulsation in large venules and veins
where oxygen saturation is lower than in arteries. This induces an error to the sig-
nal because in presence of both venous and arterial pulsations pulse oximeter cannot
distinguish the arterial pulsation. [3]
Low peripheral blood perfusion caused by hypothermia, low cardiac output, vaso-
constriction or hypotension reduces the pulsatile volume of blood in the tissue which
reduces the signal strength and quality. This makes it difficult for a pulse oximeter
to distinguish the signal from the background noise. [2, 36]
Ambient light from sources such as fluorescent light, surgical lamps, fiberoptic
instruments and sunlight causes an additional DC signal that interferes with the
optical measurement. Measurement cycle of pulse oximeters is designed to reduce
the effect of ambient light. It consist of three periods, one for each wavelength
transmission and one for ambient light measurement. Proper design and placement
of the sensor also reduce the effects of ambient light. Despite the efforts the noise
from the ambient light still remains in the measured signal. Also light from the
LEDs will cause an error if it reaches the detector without passing through pulsatile
arterial bed (optical shunting). [2, 30]
Transient motion is a significant source of error and cause of false alarms. Even
tiny movements add artifacts to the plethymosgraphic signal because the AC com-
ponent is only 1-2 % of the total transmission. Some of the motion artifacts such
as shivering, seizure activity, repetitive cough or exercise can be removed by signal
processing methods or visually observing plethymosgraphic signal but artifacts in
the cardiac frequency range are difficult to distinguish. [2, 30]
Calibration assumptions and methods cause also errors in the measurement.
Calibration is usually done for saturation range 70− 100 %. Pulse oximeters have
been shown to be inaccurate when oxygen saturation is less than 75 %. Subject
variability and use of human adult hemoglobin are also sources of error. [3]
Other possible sources of errors in pulse oximetry are skin pigmentation and sen-
sor type [37], magnetic resonance imaging, improper probe position, supplementary
oxygen, or various medical conditions. [2, 3, 30]
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2.3 Multi-wavelength pulse oximetry
Conventionally total hemoglobin concentration and dyshemoglobin fractions are
measured with CO-oximetry. CO-oximeter availability in hospitals is poor [29] and
cost effective and non-invasive user friendly tool for measuring total hemoglobin and
true fractional hemoglobin values is needed.
Fractional multi-wavelength pulse oximetry would increase the accuracy of arte-
rial oxygen saturation measurement and detect carboxyhemoglobinemia and methe-
moglobinemia. Specially in a busy emergency department (EDs) or pre-hospital or
emergency medical services (EMS) area, a device that would identify unexpected
CO poisoning might lead to early detection and treatment of the condition [38–41].
Ash-Bernal et al [15] recommended frequent CO-oximeter tests to detect and treat
methemoglobinemia.
The total hemoglobin (tHb) blood test is one of the most ordered laboratory test
in acute and outpatient settings. In United States, tHb measurement is performed
over 400 million times per year [42]. Non-invasive and continuous hemoglobin or
hematocrit (proportion of blood volume that is occupied by red blood cells) mea-
surement would provide immediate information of patient’s red blood cell concentra-
tion. In particular, the benefits would be in area of blood transfusions and general
fluid management. One possible application would be increasing patient safety and
comfort in all care areas where tHb measurements are needed. For example com-
mon blood sample test for detecting anemia could be replaced with non-invasive
tHb measurement. [20]
This section reviews the theory and calibration methods of multi-wavelength
oximetry. At the end current solutions in multi-wavelength oximetry are reviewed
2.3.1 Theory of multi-wavelength pulse oximetry
The Beer-Lambert theory for pulse oximetry presented in previous section 2.2.2 can
be generalized to apply for a multi-wavelength system. For a system of n wavelengths
and m analytes Equation 6 can be expressed with the following matrix notation,
dA
LB
λ1
...
dALBλn
 =
∆lλ1 · · · 0... . . . ...
0 · · ·∆lλn

ελ1,HbX1 · · · ελ1,HbXm... . . . ...
ελn,HbX1 · · · ελn,HbXm
 ·
HbX1...
HbXm
 · c(Hb), (16)
where dALBλ is the differential absorption within the Beer-Lambert model, ελ,HbX
is the millimolar extinction coefficient, HbX are hemoglobin fractions, ∆lλ is the
optical path-length for wavelength λ and c(Hb) is the hemoglobin concentration.
In Beer-Lambert model, path-length is independent of the wavelength. This linear
equation can be solved only if m is equal or greater than n, which means that at
least four wavelengths are needed to solve four hemoglobin species.
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2.3.2 Calibration of multi-wavelength pulse oximeter
No widely accepted calibration method for multi-wavelength pulse oximetry have
been published. Few methods have been presented in patents but none of these
have been commercialized.
Jarman [43] presented a direct calibration method for calculating hemoglobin
fractions. She expanded the conventional method to four wavelengths and applied
a direct model for all hemoglobin species in the blood as presented in equation
HbX =
a1 ∗ dA1 + a2 ∗ dA2 + a3 ∗ dA3 + a4 ∗ dA4
b1 ∗ dA1 + b2 ∗ dA2 + b3 ∗ dA3 + b4 ∗ dA4
, (17)
where dAλ is the differential absorption signal, ai and bi are calibration coef-
ficients experimentally determined over a large population average. In 1999, she
modified the calibration process to include two stages, where methemoglobin frac-
tion was first determined with one set of calibration coefficients and a second cali-
bration round was used to solve oxyhemoglobin, reduced hemoglobin and carboxy-
hemoglobin fractions. [44]
Aoyagi et al. [45] presented a different approach for the calibration. Instead of
Beer-Lambert model they applied Schuster’s theory of radiation through a foggy
atmosphere to the multi-wavelength system. They added a wavelength neutral scat-
tering plate in front of the light source to change the direction of the incident light.
In addition, they included the effect of tissue and venous blood in their equations.
Although in the patent [46] regarding the same approach they claim to solve for
all hemoglobin species the latter publication [45] only refers to improvements in
conventional pulse oximetry.
Huiku et al. [47] suggested that the above methods include several erroneous as-
sumptions. Direct modeling of hemoglobin species is not possible because a system
of equations presented in Equation 16 is not linear in real tissues. In-vivo extinction
coefficients used in the equations are functions of the concentrations themselves,
which means that constant calibration coefficients cannot be found. In their pro-
posal, they transform the in vivo measured ratio-of-ratios, Rin−vivo, first to the
corresponding Beer-Lambert ratios, RLB, as presented in equation
RLB = fλ1,λ2(Σa,Σs)Rin−vivo, (18)
where the transformation, f , depends on the total tissue scattering (Σs) and
absorption (Σa) at wavelengths λ1 and λ2 but not anymore on the hemoglobin
fractions. The absorption dependence refers to the total absorption in the whole
tissue. Then information of the analyte composition is not needed as photons do not
care what kind of absorption center they encounter in the tissues. The path-lengths
in Equation 16 vary in the tissues. The transformation is based on path-length
multipliers (PLMs), which tell how much the path-lengths change as a function of
tissue absorption and scattering. [48] A tissue model is generated using three tissue
layers (epidermis, bloodless dermis and blood) and the normal values for tissue
parameters reported in the literature. PLMs and tissue model coefficients are found
using the tissue model that reproduces the calibration for a two wavelength standard
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oximetry. The calibration for other wavelengths can be found using the tissue model
and calibration data collectionis not needed.
On the left side of Figure 12, path-length multiplier (PLM) represents the trans-
formation as a function of tissue parameters that are incorporated in the quantity
Σa/Σs. When the absorption increases only the photons that travel the shortest
route through the tissue can reach the detector and the PLM is near one. As ab-
sorption decreases also photons that travel longer routes can reach the detector.
When photons scatter a lot they rarely reach the detector and the PLM is near one
as only photons that do not scatter reach the detector. The transformation curve
for standard pulse oximetry derived with the tissue model is presented on the right
side of the Figure 12. [47]
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Figure 12: On the left: Path-length multiplier (PLM) as a function of tissue optical
character parameter Σa/Σs of the transformation model obtained from the calibra-
tion data of conventional pulse oximetry. On the right: transformation model for
the standard pulse oximetry. [47]
2.3.3 A commercial multi-wavelength pulse oximeter
In 2005, Masimo Corporation released a commercial device Rad-57 Pulse CO-Oximeter
for noninvasive and continuous fractional hemoglobin measurement. Accuracy of
methemoglobin measurement (SpMet R©) is specified to ± 1 % for a range from 1 to
15 % and for carboxyhemoglobin measurement (SpCO R©) to ± 3 % for a range from
1 to 40 % [49]. There has been controversy reports on the accuracy and usefulness
of this device to detect carboxyhemoglobinemia [38–41, 50–56]. Table 4 lists the
authors, year, settings and the results of the studies reporting SpCO bias and pre-
cision. Generally the results are a bit worse than the specifications. In some studies
a significant bias is present and in some precision is poor.
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Table 4: Accuracy of SpCO measurement
Authors Year Setting Bias (%) Precision (%)
Mottram et al. [50] 2005 Respiratory department 2 1.8
Barker et al [51] 2006 Laboratory -1.2 2.2
Layne et al. [52] 2006 pulmonary lab -0.65 1.8
Layne et al. [52] 2006 ED -0.54 4.34
Coulange et al. [38] 2008 ED -1.5 2.5
Suner et al. [40] 2008 ED -4.2
Kot et al. [53] 2008 Hyperbaric center 0.5 4.3
Piatkowski et al. [54] 2009 burn center 3.2 2.4
Touger et al. [55] 2010 ED 1.4 6.6
Roth et al. [56] 2011 ED 2.99 3.27
Only three studies are conducted on the methemoglobin accuracy. Results are
presented in Table 5. In the study by Feiner et al. in 2009 methemoglobin accuracy
was unacceptable. Also SpO2 readings were underestimated as methemoglobin level
increased. [57] A more recent article from Feiner et al. [58] reports acceptable accu-
racy for HbMet over saturation range of 74− 100 % and HbMet range of 0− 14 %.
In the latter study, a new probe was used and software was modified by Masimo to
improve the performance.
Table 5: Accuracy of SpMet measurement
Authors Year Setting Bias (%) Precision (%) ARMS (%)
Barker et al. [51] 2006 Laboratory -0.17 0.59 N/A
Feiner et al. [57] 2009 Laboratory 7.7 13.0 15.1
Feiner et al. [58] 2010 Laboratory 0.16 0.83 0.84
Because hemoglobin is the strongest absorber in the blood, spectrophotomet-
ric methods have been investigated to measure tHb. Inter-patient variations, con-
centrations of other chromophores such as melanin and various flavins, the pres-
ence of dyshemoglobins and changes in the optical path-length have been the main
challenges in spectrophotometric methods. [20] At the end of 2008 Masimo Cor-
poration introduced Pulse CO-OximetryTM for noninvasive, immediate and contin-
uous hemoglobin measurement (SpHb) using multi-wavelength spectrophotometric
method. Macknet et al. [42] compared SpHb values to invasive CO-oximetry results
from twenty healthy subjects undergoing hemodilution. They reported a bias of
−0.15 g/dL and precision of 0.92 g/dL from 165 samples, which fulfills the accuracy
specification of the manufacturer (1 g/dL).
Based on the studies reported above usefulness of the Masimo technology is not
obvious and more clinical evidence from different settings are needed before the
measurements will be widely accepted for clinical use.
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3 Materials and methods
This thesis is a part of project that aims to develop a multi-wavelength pulse oxime-
ter that measures fractional hemoglobins and total hemoglobin. The project has
been ongoing since 2008. Figure 13 presents the main tasks of the project consisting
of goal setting, prototype development, data collection, data analysis, and fractional
pulse oximetry (FrOx) algorithm development. Future work includes prototype en-
hancements and the development of total hemoglobin (tHb) algorithm based on the
knowledge achieved during the project. The part that this thesis is about, data
analysis and algorithm development, is marked with an orange box.
Goal
Setting
Prototype
development
Clinical
studies
Data analysis
and fractional
pulse oximetry
algorithm development
Future work
Figure 13: Hemoglobin project
This section first reviews the previous steps of this project, goal setting, proto-
type development, and data collection. After this methods used in data analysis
and algorithm development are discussed in more detail.
3.1 Goal setting
The goal of the project is to develop a multi-wavelength oximeter that measures frac-
tional hemoglobins and total hemoglobin with a single device. Clinically relevant ac-
curacy for the measurement algorithm for hemoglobin species and total hemoglobin
was determined through interviews with clinicians and a literature analysis. Lit-
erature analysis of this thesis further confirmed the requirements for algorithm ac-
curacy. [15, 20, 26, 40, 55, 56, 58] Requirements are presented in Table 6 for different
saturation levels. Requirements are presented as percentage points away from the
true value. Other requirements for the algorithm are robustness and simplicity.
Table 6: Clinically relevant accuracy requirements for fractional hemoglobin and
tHb measurements.
SaO2 SpO2 HbO2 HbCO HbMet tHb
(range) (40− 100 %) (40− 100 %) (0− 80 %) (0− 80 %) (30− 200 g/L)
100− 90 % ± 2 % ± 2 % ± 3 % ± 1 % ± 10 g/L
90− 70 % ± 2 % ± 2 % ± 5 % ± 2 % unspecified
70− 40 % unspecified unspecified unspecified unspecified unspecified
The literature review shows that a screening tool for recognizing elevated dyshe-
moglobin levels would be useful. Dyshemoglobin thresholds that are relevant for
clinical diagnosis of dyshemoglobinemia are set to 2 % with elevated HbMet and to
6 % with elevated HbCO.
24
3.2 Prototype development
During 2008 a multi-wavelength data collection unit shown in Figure 14 was built.
It consists of several prototype measurement units, serial data collection interface
unit and a laptop for data storing. The purpose of the development of the device
was to expand the conventional two-wavelength technology to eight wavelengths.
Figure 14: Data collection system of eight measurement modules and probes, serial
data collection interface unit and a laptop for data storing.
To achieve the goal, the existing oximetry hardware and software were modified.
The new sensor includes eight LEDs and an NTC resistor for temperature measure-
ment. Figure 15 presents a high-level block diagram of the measurement module.
The design is a copy of a conventional pulse oximeter design that is multiplied to
eight wavelengths. The biggest difference is the LED switch that takes care of the
multiplexing of control and demultiplexing of measurement signals. Other parts such
as a microprocessor, a LED drive, a front end, analog-to-digital (A/D) converter, a
module bus and a power block can be found from conventional oximeters. [59]
Figure 15: A block diagram of a measurement module
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The optimization of wavelengths in sensor is difficult as several criteria must be
taken into account. Wavelengths need to be selected from the tissue transmission
window, which ranges from 600 to 1300 nm. At wavelengths shorter than 600 nm
skin pigment and other tissue components have too high absorption and at longer
wavelengths than 1300 nm the high absorption of water disturbs the measurement.
Since LED emission is not exactly monochromatic and it changes as a function
of temperature, wavelengths were selected from the regions were the spectrum is
not changing fast to minimize the effect of the possible wavelength shifts. This
means that the minimums and the maximums of absorption curve are good choices.
Isobestic points were favored as they are good reference wavelengths. In addition,
differential absorptions should be sensitive to changes in the hemoglobin fractions
which means that there should be clear differences between extinction coefficients.
[3, 47] To keep the costs low wavelengths should be selected from a range where
silicon photodiode can be used as a detector. The selected LED center wavelengths
(612 nm, 632 nm, 660 nm, 690 nm, 730 nm, 760 nm, 800 nm, and 890 nm) are shown
as vertical lines in Figure 16 with hemoglobin extinction curves. [59]
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Figure 16: Extinction coefficients of hemoglobin species in the range of 570 nm to
1000 nm.
The prototype was tested against safety, regulatory compliance and technical
specifications listed in Table 7. Performance testing including electromagnetic com-
patibility (EMC) test, electrical safety test, sensor surface temperature test and
cross talk and noise measurements showed that the device is suitable for clinical
tests and that the performance is comparable with standard pulse oximetry. [59]
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Table 7: Prototype specifications [59]
Safety and compliance Description/Limit
Patient isolation 1500 V (DC)
Maximum sensor temperature 41 ◦C
Max LED fault current 20 mA (continuous)
RoHS compliance Compliant with appropriate standards
EMC compliance Emissions shall be compliant with
appropriate standards
Technical features Description/Limit
Input voltage 15 V DC (from host monitor or power source)
Sampling rate 100 Hz
Signal performance 12 bits signal resolution (noise free bits)
Output data 8 channels of 19 bit plethysmographic waveform
Communication Asynchronous RS232 serial communication
Option for RS485 communication with host monitor
Wavelengths 600− 1000 nm
Temperature measurement Accuracy 0.1 ◦C, Range 20− 50 ◦C
Adjustable LED currents 20− 300 mA
Adjustable gain At least two gain options.
Common for all channels
Noise measurements were done with three different-sized test fingers. Noise free
bits were calculated as a logarithm of two of the SNR. This tells the measurement
resolution for the noiseless signal. Results presented in Figure 17 show that noise
free bits decrease along the absorbance. With the thickest test finger (attenuation
level 19) accuracy decreases to an insufficient level and some channels have very
low performance. These problems arise mainly from the prototype’s inability to
control LED currents and channels gains to an optimized signal level for the AD
converter. [59]
Figure 17: Noise measurement results expressed as noise free bits with different
attenuation levels (low = 4, medium = 7 and high = 19) [59].
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3.3 Clinical data collection
Clinical data collection was started after the prototype was accepted for use. Clin-
ical studies were designed to cover wide enough parameter range for SpO2, HbCO,
and HbMet. Development data collection process is presented in Figure 18. Vol-
unteer test subjects were recruited in the studies. Plethymosgraphic signals and
reference blood data from CO-oximeters were stored for further off-line analysis
with MATLAB R©. This section explains in more detail when, where and how the
data was collected. The clinical study protocols are described at the end.
Test subject Prototype device
with measurement
sensor on 7 fingers
Blood sampling
and analysis
with CO-oximeters
Eight plethymosgraphic
signals and hardware
adjustment data
for each sensor
Reference data
(time stamps, HbX, tHb)
Oﬄine analysis
with MATLAB
Figure 18: Data collection
The development studies for dyshemoglobin measurements included three sep-
arate studies. In the first study in April 2009, smoker volunteers were recruited.
Normal dyshemoglobin study was conducted in January 2010 and elevated dyshe-
moglobin study in March 2010. The covered ranges in these three studies are shown
in Figure 19. For HbCO and HbMet ranges of 0− 20 % were in target but due to
ethical issues only range of 0− 15 % was achieved. SaO2 range from 70 to 100 %
was achieved in all studies. Altogether about 500 blood samples were drawn from
the volunteer test subjects. Additional outcome from the normal dyshemoglobin
study was preliminary data collection for tHb algorithm development. [60]
3 subjects
7 devices
∼20 blood
samples
≈400 data
points
11 subjects
7 devices
∼16 blood samples
≈ 1200 data points
10 subjects
7 devices
∼13 blood samples
≈ 900 data points
6 subjects, 7 devices, ∼20 blood samples ≈ 800 data pointsH
b
M
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2-10 %
0-2 %
HbCO
0-5 % 5-10 % 10-15 %
Figure 19: Collected clinical data coverage
Smoker and normal dyshemoglobin studies were conducted in Clinimark lab-
oratories and elevated dyshemoglobin study was conducted in the laboratory of
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Department of anesthesia and perioperative care, University of California at San
Francisco. Both laboratories use several CO-oximeters and multiple syringe runs to
be able to reduce analytical errors. [27] Subjects that had deeply pigmented skin
color, Body Mass Index (BMI) less than 15 or greater than 35, neurological disor-
der, diabetics, history of cardiac disease, and recent use of psycho-active medication
were excluded. To cover different finger sizes and to study the effect of cushion color
seven probes were used with each subject. Probes were attached to the fingers as
listed in Table 8.
Table 8: Probe units attached to the fingers
Unit number Cushion type Finger
1 white left middle
2 white left ring
3 white left pinky
4 white left/right thumb
5 black/white* right index
6 black right middle
7 black right ring
*unit type changed in January 2010 study
Eight plethymosgraphic signals from the seven prototypes, the hardware adjust-
ment data and time were recorded using a PC. Blood samples were drawn from
the subjects and they were analyzed with CO-oximeters. IL 682 CO-Oximeter and
Radiometer OSM A hemoximeters were used in April 2009 and January 2010 stud-
ies. Radiometer ABL 800 FLEX and OSM hemoximeters were used in March 2010
study. Precisions reported by the manufacturers of these CO-oximeters are presented
in Table 9. Reference data (fractional hemoglobins, tHb, and time of blood sam-
ples) were stored manually and electronically and delivered to the GE hemoglobin
research group for further analysis. [60]
Table 9: Precision of CO-oximeters used in the clinical studies reported by manu-
facturers [61–63]
Manufacturer & Device Abbreviation Precision (±1 SD)
HbO2 HbCO HbMet
Radiometer OSM-3 OSM 0.4 - 0.7 0.5 - 0.6 0.4
Instrumentation Laboratory IL 0.5 0.5 0.5 (0-10%)
682 CO-oximeter 1 (10-100%)
Radiometer ABL 830 FLEX ABL 0.5 0.4 - 0.75 0.3 - 0.4
Smoker and normal dyshemoglobin studies followed a protocol that is depicted
in Figure 20. At each stable level at least two arterial blood samples and one venous
sample were drawn. First blood samples were taken in room air situation. Then
blood volume in the finger was changed by lifting the hands above the heart. When
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the hands were up no blood samples were drawn. After hands were returned back
to the resting position, situation was stabilized and blood samples were drawn. In
desaturation phase, arterial blood saturation was reduced gradually to two levels:
92− 88 % and 82− 78 %. In supersaturation phase, the saturation was raised with
100 % oxygen to a fully saturated blood level for 3–5 minutes. Last blood samples
were taken after the subject was returned to the room air oxygenation level.
1st
baseline
Hand lifting
2nd
baseline
Desaturation Supersaturation
3rd
baseline
Figure 20: Protocol for data collection in smoker and normal dyshemoglobin studies.
Figure 21 presents a flow diagram of the protocol for elevated dyshemoglobin
study that can be separated in two studies: carbon monoxide inhalation and nitride
infusion study. In carbon monoxide inhalation study, carboxyhemoglobin level was
altered by inhalation of CO/air mixture boluses until HbCO level reached 10 %. For
safety reasons blood samples were drawn regularly at 2-3 minutes intervals. Before
the desaturation phase subjects were interviewed to make sure that they feel well
and want to continue to the desaturation phase similar to described above. After de-
saturation phase CO/air mixture inhalation was continued until HbCO level reached
15 %. Then subjects were recovered with 100 % oxygen mixture and followed up as
long as HbCO level was less than 10 %.
In nitride infusion study, changing HbMet levels were achieved by infusion of
sodium nitride (NaNO2) using a calibrated commercial infusion pump. First infusion
phase was continued until HbMet level reached 5 % and the second phase was ended
when the level reached 10 %. Subjects were recovered with 50 % oxygen mixture
and followed as long as HbMet level was less than 5 %. Otherwise the protocol was
similar to the carbon monoxide inhalation study.
Room air
CO/air mixture
inhalation or
NaNO2 infusion
Desaturation
CO/air mixture
inhalation or
NaNO2 infusion
Recovery phase
Figure 21: Protocol for data collection in elevated dyshemoglobin study.
3.4 Data analysis and algorithm development
The purpose of this thesis was to analyze the data that have been collected with the
prototype device. Data analysis and algorithm development process can be divided
in five steps as presented in Figure 22. Analysis was done off-line with MATLAB R©
environment for algorithm development. First reference CO-oximeter data is ana-
lyzed. Then plethymosgraphic data is preprocessed using signal processing methods
of conventional pulse oximetry. After preprocessing the quality of the data is checked
using statistical methods. In algorithm development statistical methods are used to
find a regression model for fractional hemoglobins. Few different methods are used
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and compared to each other. The best algorithm is validated using cross-validation
techniques. In this section, the process is described in more detail.
CO–oximeter
data analysis
Preprocessing of
plethymosgraphic
signals
Data quality
analysis
Algorithm
development
Algorithm
validation
Figure 22: Data-analysis and algorithm development process.
3.4.1 CO-oximeter data analysis
CO-oximeter data points that were more than three standard deviations away from
the mean were excluded. In addition, data accuracy was evaluated using Bland-
Altman method. Bland and Altman method is a recommended analysis method for
reporting and presenting CO-oximetry errors [28]. In Bland and Altman procedure,
two methods of which neither can be stated to give the true value are compared.
In Bland-Altman plot, difference between two measures is plotted against their
average. From a data set mean and standard deviation of differences are calculated
and marked in the plot as straight lines. [64] Bland-Altman plots are also used in
evaluating pulse oximetry performance [26]. An example of Bland-Altman plot for
conventional pulse oximetry data is shown on the left side of the Figure 23. On
the right side the data set is pooled. Bias is marked with an asterix and SDs with
whiskers.
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Figure 23: On the left: Bland-Altman plot of CO-oximetry data. On the right:
Pooled data summary plot with mean and standard deviation.
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3.4.2 Data preprocessing
This section describes how plethymosgraphic signal is processed and how different
parameters such as ratio-of-ratios (Rs), DC component, and perfusion index (PI)
are derived from plethymosgraphic signal. Block diagram of preprocessing steps is
presented in Figure 24. Yellow circles represent quality parameters that are calcu-
lated from the signals and they are further discussed in the next section. Red circles
are parameters derived from plethymosgraphic signal. Green rectangles represent
processing steps and blue ellipses are signals used in pulse oximetry.
Raw signal
Hardware
adjustments
Transmission
signal
Filtering
Peak and
valley
recognition
Fast Fourier
Transform
Plethymosgraphic
signal
Respiratory
signal
Auto-
correlation
Delta
absorption
method
RdA
Respiratory
modulation
Rresp
RFFTn RFFT
DC
component
Rpv
PI
HW
quality
Figure 24: Block diagram of preprocessing steps
First raw data is adjusted with gain and LED drive current recorded from the
hardware system to obtain transmission signals.
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Peak and valley recognition is applied to the transmission signal. Peak values
are stored as a DC component of the signal. Perfusion indexes are derived from the
difference between peak and valley values. In addition, peak and valley method of
ratio-of-ratios calculation is applied to the signal.
Transmission signals are filtered with generalized Butterworth filter that unifies
the classical Butterworth filter and the maximally flat symmetric FIR (finite impulse
response) filter. A high pass filter with cut-off frequency at 0.4 Hz produces the AC
part of the signal. To reduce high frequency noise a low pass filter with cut-off
frequency at 10 Hz is used. Respiratory signal is obtained with a band-pass filter
from 0.1 Hz to 0.4 Hz. These digital filtering steps are all performed twice, forth
and back, to eliminate group delays. Generalized Butterworth filters provide a good
trade-off between performance and implementation complexity, which is important
when the algorithm is applied to the final product. [65]
After filtering respiratory modulation ratios are calculated to obtain respiration-
induced venous blood volume changes. Autocorrelation coefficients of the plethy-
mosgraphic signals are calculated to recognize signal artifacts. Delta absorption
model and Fast Fourier transform (FFT) are used in ratio-of-ratios calculations
that are further explained in the following section.
Methods of ratio-of-ratios calculations
Three different methods - peak and valley method, delta absorption model and the
fast Fourier transform - were used in the thesis to calculate ratio-of-ratios, Rs (Eq. 8)
for a multi-wavelength system.
Traditionally peak and valley method has been used. Peaks and valleys for each
cardiac cycle are recognized from the transmission signal and the delta absorption
(Eq. 7) is used to calculate ratio-of-ratios, Rpv, as shown in equation,
Rpv =
dAλ1
dAλ2
=
ACλ1/DCλ1
ACλ2/DCλ2
. (19)
Figure 25 presents the transmission intensity as a function of time and the rec-
ognized peak and valley for R calculation using two different wavelengths (660 nm
and 800 nm).
In delta absorption model, dA is calculated by dividing the intensity of two
successive measurements by the average of the intensities for each wavelength as
presented in equation,
dAλ =
Ii − Ii−1
(Ii + Ii−1)/2
, (20)
where Ii and Ii−1 are intensities of subsequent observations. Delta absorptions
for two different wavelengths are plotted in xy scatter plot and a straight line is
fitted to the data so that the sum of squares of perpendicular distances to the line
is minimized. An example of a fit using the same data points as in peak and valley
method, is shown in Figure 26. Ratio-of-ratios, RdA, is the slope of the line and the
constant can be used as a measure of the goodness of the regression. The constant
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Figure 25: Peak and valley method
should be very near to zero, otherwise some kind of artifact is present in one of the
signals. Also the sum of squares of perpendicular distances to the line can be used
as a measure of the fit goodness. [66, p.288–292]
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Figure 26: Delta absorption model
The fast Fourier transform (FFT) can be used to calculate ratios. FFT is an
effective algorithm to compute discrete Fourier transform (DFT). Fourier transform
is a mathematical operation that transforms the signal depending on time to a
frequency domain. Since plethymosgraphic signal is periodic transforms using si-
nusoidal base functions should be good tools for analysis. The AC component is
derived from FFT as the highest spectral line at the cardiac frequency (1− 2 Hz)
and DC component as the zero frequency component of the composite signal. After
this RFFT is obtained using Equation 7. To obtain the amplitude of the AC compo-
nent of the plethymosgraphic signal accurately, the time interval should be at least
one period as transform error reduces with longer time interval. [67] Figure 27 shows
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a sample of FFT output excluding the large zero frequency component. Ratio-of-
ratios RFFTn are also calculated with FFT directly from the differential absorption
signal using a Hamming window to smoothen the boundaries.
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Figure 27: Output of a sample FFT from the transmission signal.
3.4.3 Data quality analysis
In this thesis, data that is too noisy to provide useful information was rejected.
Correction algorithms were not used. Hardware adjustment and autocorrelation
coefficient signals were used to track data quality.
Hardware adjustments, such as gain or LED drive current changes, that might
cause artifacts in the signal for a short period of time, were stored. A common HW
adjustment signal was formed to reject data in presence of hardware adjustments.
Figure 28 shows an example a successful data rejection due to hardware adjustment.
Many signal artifacts created by movements or other external sources are present
in all signals. As plethymosgraphic signal is periodic and should not have big changes
in a short time period autocorrelation coefficient is used to recognize pulse to pulse
variations. Autocorrelation coefficient signal is calculated with equation
acorr(t) = maxτ∈[0.3s···2s]
(
1
N
∑t+2.5s
n=t−2.5s xλ(n)xλ(n− τ)
1
N
∑t+2.5s
n=t−2.5s x
2
λ(n)
)
, (21)
where xλ is the zero average plethymosgraphic signal, τ is the delay in time andN
is the number of samples. Five second window is used in the calculation to make sure
that at least three pulses fit in the window even with low heart rate. Autocorrelation
coefficient signals are calculated with 1 second resolution. Rejection limit is set to 0.7
and signals are stored for all wavelengths. A total autocorrelation coefficient signal
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Figure 28: An example of successful data rejection due to hardware adjustment.
is created to indicate if the limit is violated with any of the wavelengths. Figure 29
presents a successful signal artifact recognition by autocorrelation coefficient signal
while simultaneous hardware quality signal shows that artifact is not arising from
hardware adjustments.
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Figure 29: A successful rejection based on autocorrelation coefficient signal.
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3.4.4 Development data selection
Development data was visually segmented around the blood samples to indicate good
data quality. Only zero average plethymosgraphic signals are inspected using signal
viewer SigView 3.11m (VTT Technical Research Center of Finland). Acceptance
criteria for good signal are defined as repeating pattern in the signal without sudden
big changes in the amplitude or in the period. If possible, segment is selected 15
seconds around the recorded time stamp. Selection of two shorter time periods is
also accepted. Periods are required to be within 60 seconds around the sample.
A snapshot of a good quality signal taken with SigView is presented in Figure 30.
Plethymosgraphic signals of different wavelengths are shown in the upper panel. The
lower panel shows the hardware quality signal. Vertical lines indicate the selected
time interval and the blood sample time.
Figure 30: An example of a good data interval
Traditional SpO2 values and noise of ratio-of-ratios are calculated from the visu-
ally segmented time intervals. Noise is calculated as the relative standard deviation
defined in equation
%RSD = 100% · RSD,λ
R¯λ
, (22)
where RSD,λ is the standard deviation and R¯λ is the mean of ratio-of-ratios in
the evaluation period at wavelength λ.
The total noise in hemoglobin fractions can be estimated with equation
∆HbX =
√
n2COox + n
2
instrumental + n
2
physiological, (23)
where nCOox is the error in CO-oximetry results, ninstrumental is the noise in
ratio-of-ratios calculations and nphysiological is the subject-to-subject variability. The
accepted noise in hemoglobin fractions is defined in Table 6. All data points, where
the total noise exceeds the accuracy requirement, are rejected from the development
data set to make sure that the development data quality is good.
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3.4.5 Algorithm development
Fractional pulse oximetry (FrOx) algorithm presented in Figure 31 is developed to
solve hemoglobin fractions (HbX) from set of equations presented in Equation 16.
The equations are linearized by establishing the path-length transformation from
the in vivo measured signals to the corresponding non-scatter signals in the Beer-
Lambert model using parameters derived from the preprocessing phase. Also ef-
fective extinction coefficients are derived through extinction compensation. Then
linear set of equations is solved to derive analyte concentrations.
Parameters derived from
plethymosgraphic signal
Rin−vivo, Rresp, P I, FLT
Parameters from hardware
LED,DET,Gain
Extinction coefficients
ε
Beer-Lambert
transformation of Rs
RLB = g(Rin−vivo, P )
Extinction compensation
ε˜ = h(ε)
Linear inversion solution
Analyte concentrations
HbX
Figure 31: Steps included in fractional pulse oximetry algorithm
Extinction compensation
To address deviations from the theoretical model, extinction coefficients in Equa-
tion 6 need to be replaced with effective extinction coefficients defined in equation
ε˜λ,HbX =
1
W
∫
LEDλ,T ·DETλ · ελ,HbX ·FLTλdλ, (24)
where LEDλ,T is the temperature(T)-dependent spectral intensity of the LED,
DETλ is the spectral photodetector sensitivity, ελ,HbX is the Beer-Lambert extinc-
tion curve for hemoglobin species HbX and FLTλ, functional light transmission, is
wavelength-dependent transmission of the tissue and W =
∫
LED ·DET ·FLT · dλ
is the normalization factor. [68]
First term takes into account deviations in the LEDs. LEDs are not monochro-
matic as their spectral bandwidth is typically in the range from 20 to 60 nm. The
bandwidth increases with the wavelength, which can be seen from the Figure 32
that presents a typical LED emissions used in a multi-wavelength probe. [2]
In addition, the center wavelength of the LED shifts due to temperature changes.
This can be corrected by measuring the temperature of the sensor and using cor-
rection function derived from the manufacturer. In addition, different drive cur-
rents of LEDs change the temperature of a particular LED. Especially with shorter
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Figure 32: Typical spectrums of LEDs used in a probe
wavelengths than 660 nm the temperature change can be significant in this multi-
wavelength system. Secondly the wavelength-dependent sensitivity of the photode-
tector is taken into account in the extinction compensation. [2, 68]
One part of extinction compensation is the calculation of tissue prefiltering effect.
Functional light transmission (FLTλ) at wavelength λ makes different DC values
comparable to each other. FLT is defined according to equation
FLTλ =
fCTRλ
CTRλ
, (25)
where CTR is Current Transfer Ratio measured from the probe without tissue
between the LEDs and the detector and fCTR is functional Current Transfer Ratio
measured with finger in the probe. CTR is derived from DC light signal in absence
of tissue that is normalized to correspond to an emitter current value of 1 mA. CTR
is a measure of sensor characteristics such as the color and the geometry of the probe
as it tells how efficiently light is transmitted from the LED to the detector. fCTR is
a measure of tissue properties and can be determined from the DC light transmis-
sion signal after gain and current normalizations. FLT as ratio of fCTR and CTR
describes light attenuation caused by the tissue as probe design characteristics are
ruled out. Now spectral transmission can be estimated from the measured DC trans-
mission values by interpolating the data. Values outside prototype wavelengths are
estimated from previous spectrophotometric measurements. An example of tissue
transmission derived this way is presented in Figure 33. [68]
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Beer-Lambert transformations of ratio-of-ratios
In FrOx formalism, Beer-Lambert transformations represent the calibration of nor-
mal pulse oximeters by linearizing the set of equations so that they can be solved.
Mathematically these transformations can be expressed as
RLBλ = g(R
in−vivo
λ , Pλ), (26)
where RLBλ is the non-scatter Beer-Lambert ratio-of-ratio, R
in−vivo
λ is the mea-
sured ratio-of-ratios, Pλ describe tissue properties affecting the path-lengths and
g is the transformation function. In this thesis, the transformation, g, is estab-
lished by regression of the Beer-Lambert ratio-of-ratios back-calculated from the
measured blood sample hemoglobin concentrations to the corresponding measured
in-vivo ratio-of-ratios calculated with delta absorption method described in previous
section 3.4.2.
Regression of RLBλ is done with few regression methods. First parameters that
most likely contain information of the tissue properties are selected to the model.
List of selected parameters is presented in Table 10. Principal component analysis
(PCA) and step-wise regression methods are used in the modeling of the transfor-
mations.
Principal component analysis converts a set of possibly correlating parameters
into a set of uncorrelated parameters called principal components. In the transfor-
mation the first principal component represents the greatest amount of variability
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Table 10: Parameters used in regression modeling
Parameter (Pλ) Description
Rλ Ratio-of-ratios at wavelength λ
FLTλ Functional light transmission at wavelength λ
PIλ Perfusion Index at wavelength λ
RR Respiratory modulation depth
in the original data set. Determination of principal components is done using sin-
gular value decomposition. The number of principal components is calculated with
different ways. First the number is required to account for 95 or 99 percent or of
the variance. Then all principal components that account at least 0.5 percent of
the variance are included. As comparative method scree plots are drawn to find
a clear breakpoint after which variance is not decreasing significantly anymore. In
scree plot, eigenvalues (representatives of the variance) are drawn as a function of
ordered principal components. Sometimes ’an elbow’ can be seen in the scree plot
which gives an estimate how many principal components are significant. Examples
of scree plots are presented in Figure 34. On the left side of the figure a clear elbow
is seen as on the right side the curve is smooth. [69]
2 4 6 8 10
0
0.2
0.4
0.6
0.8
1
NBR of principal component
Ei
ge
nv
al
ue
2 4 6 8 10
0
0.2
0.4
0.6
0.8
1
NBR of principal component
Ei
ge
nv
al
ue
Figure 34: On the left: Scree plot with a clear elbow. On the right: A scree plot
with smooth eigenvalue curve.
Forward selection method presented in Figure 35 is used in step-wise regression.
Parameters are included in the model in the following order: linear terms, quadratic
terms, third-order terms and cross-product terms. In forward selection method,
parameters are included in the model one after another with criteria of the greatest
decrease in the mean square error. In statistics, several methods for choosing the
number of parameters in the model can be used. In this thesis, Schwarz Bayesian
information criterion (SBIC) and F-tests are used. SBIC is an unbiased and efficient
criterion in that sense that all accountable but none of the unnecessary terms are
included in the model. SBIC is defined in equation
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SBIC = σ2p + 2p ·
log(n)σ2p
n
, (27)
where σ2p =
1
n
∑
(g(Rin−vivoλ , Pλ) − RLBλ )2 is the error variance, p is the number
of parameters and n is the number of data points. The best model minimizes the
value of SBIC. [70]
F-test is used to test the equality of variances. Large F-values indicate that the
null hypothesis, two normal populations have the same variance, is not true. Statisti-
cal significance of parameters is tested with 90 percent confidence level (α= 90 %). If
the included parameter is not statistically significant the model is ready. Hemoglobin
fractions are solved with linear inversion solution for all stages. The fraction of val-
ues within specification, descriptive statistics and visual inspection of Bland-Altman
plots are used to compare different models.
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Figure 35: A flow diagram of the forward selection method for determining Beer-
Lambert Rs. Green rectangles represent the included parameter. Then parameters
are selected and hemoglobin fractions are solved to decide if the parameters are
needed in the model.
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Linear inversion solution
As the system is overdetermined (8 equations, 4 hemoglobin fractions) the method
of least squares is used in the inversion. The method of least squares solves the set
of equations in a way where the sum of square errors is minimized. Least squares
solution for Equation 16 in Beer-Lambert situation can be expressed with equation
HbXi︸ ︷︷ ︸
4×1
= (ETE)−1︸ ︷︷ ︸
4×4
ET︸︷︷︸
4×8
RLB︸︷︷︸
8×1
= E∗︸︷︷︸
4×8
· RLB︸︷︷︸
8×1
, (28)
where E is the extinction matrix, E∗ = (ETE)−1ET and RLB is the ratio-of-
ratios vector derived from the Beer-Lambert transformation. Second row shows the
sizes of the matrices.
When noise n is added to the system noisy estimate for a hemoglobin fraction
will be
HbXn = E
∗RLB + E
∗n = HbXi +∆HbX. (29)
The error in hemoglobin fractions ∆HbX depends on the extinction coefficients
and the actual noise. To evaluate how much noise is tolerated, robustness of the
system is analyzed using a method presented in Figure 36. Beer-Lambert ratio-of-
ratios are back calculated from the blood data and then noise is applied to see how
the noise in ratio-of-ratios affects to the hemoglobin fractions. The noise is applied
to one of the ratio-of-ratios or to all of them.
Extinction
coefficients
X
HbX
fractions
Beer-Lambert
Rs
+
Noise
Noisy
Rs
Linear inversion
solution
Noisy HbX
fractions
Figure 36: Robustness analysis of linear inversion solution. Beer-Lambert Rs are
back calculated and noise is added to them. Then hemoglobin fractions are solved
with the noisy Rs.
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3.4.6 Algorithm evaluation and validation
In this thesis, several ways of evaluating the algorithm performance are used. Stan-
dard statistics, confusion matrix and k-fold validation methods are used to evaluate
the algorithm performance. Direct modeling of hemoglobin fractions presented in
section 2.3.2 is used as comparative method. Also Bland-Altman plots of the results
are drawn.
Statistics
Bias (Eq. 13), precision (Eq. 14), and ARMS (Eq. 15) are calculated for algorithm
candidates. Another used method is to evaluate how many of the data points ac-
tually reach the accuracy presented in Table 6. If normal distribution of error and
zero bias are assumed about 68 % of the values should be within the limits.
Confusion matrix
Confusion matrix presented in Figure 37 is a good tool for analyzing the performance
of the algorithm in medical diagnostics. Confusion matrix shows the predicted and
actual classifications based on the decided limits. [71] Dyshemoglobin limits that are
relevant for clinical diagnosis were set to 2 % with elevated HbMet and to 6 % for
elevated HbCO in the goal setting phase.
Predicted
negative positive
Actual
negative TN FP
positive FN TP
Figure 37: Confusion matrix, T = true, F = false, N = negative, P = positive.
With the help of confusion matrix measures of accuracy, sensitivity and speci-
ficity can be defined:
• Accuracy = TP+TN
TP+TN+FP+FN
• Sensitivity = TP
TP+FN
• Specificity = TN
TN+FP
Accuracy describes how well the algorithm is measuring what is should measure.
Sensitivity is a measure of how many of the values classified as positive really were
positive and specificity how many of the values classified negative were correctly
classified.
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Cross-validation
Cross-validation methods are used in evaluating how well predictive models work
in practice. They show how the results of the statistical models will generalize to
an independent data set. Commonly used cross-validation methods include k -fold
cross-validation and leave-one-out (LOO) cross-validation.
In this thesis, both were used to evaluate the algorithms. k -fold cross-validation
process is presented Figure 38. In k -fold cross-validation, the original sample set is
first divided randomly into k groups. Then k -1 groups are selected for development
and the last one is left for validation. After development prediction errors are
calculated with the data points in validation set. These steps are repeated k times
and all groups are used once as a validation group. The whole k -fold cross-validation
process is repeated for several times with different division of samples. LOO cross-
validation is only a special case of k -fold cross-validation, where k is equal to the
size of original data set.
Division of data set into k groups
Development with k-1 groups
Validation with one group
Figure 38: k-fold cross-validation process
The trade-off of changing k value is in the predictive power against how repre-
sentative the result is for the larger population. The smaller the k the worse the
result should be in a given small population. On the other hand large k might result
in very good results within the small data set due to the fact that the validation
population in itself is a bad representative of the larger population.
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4 Results
Data processing was done with Matlab. This section presents all results from CO-
oximeter data analysis to algorithm validation. First reference and development
data are analyzed and the robustness of the linear inversion solution is studied.
Then different algorithm candidates are developed and compared. At the end the
best algorithm is validated.
4.1 CO-oximeter data analysis
Summary plots illustrating the CO-oximetry data accuracy are presented in Fig-
ure 39. The asterix represents the mean difference and the whiskers are plus minus
one standard deviation for the difference. Values in y-axis are difference in CO-
oximeter readings defined as OSM minus IL with smoker and normal dyshemoglobin
studies and OSM minus ABL with elevated dyshemoglobin study. Positive difference
means greater OSM values. Mean and standard deviation from smoker study are
presented with blue, from normal dyshemoglobin study with red and from elevated
dyshemoglobin study with black color. Results are consistent with the accuracies
reported by CO-oximeter manufacturers listed in Table 9. Standard deviations de-
viations for HbCO and HbMet values are clearly in specifications. For HbO2 and
RHb greater deviations exist. Also offsets between devices are present.
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Figure 39: CO-oximeter accuracy analysis using summary plots. The asterix repre-
sents the mean difference and the whiskers are plus minus one standard deviation
for the difference.
Statistical significance of the results above were tested using t-test, with null
hypothesis of zero difference in CO-oximetry readings. p-value for each case is
calculated and presented in Table 11. In most of the cases null hypothesis can be
rejected with high probability.
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Table 11: p-values of CO-oximeter analysis
HbO2 HbCO HbMet RHb
Smoker-IL1 0.72 1.00 1.00 0.16
Smoker-IL2 1.00 1.00 1.00 0.47
NormalDysHb 1.00 1.00 0.94 1.00
ElevDysHb 1.00 1.00 1.00 1.00
CO-oximeter data outliers were removed with criteria more than three standard
deviations away from the mean. Scatter plot of smoker study is presented in Fig-
ure 40. Outliers are marked with red asterixs. Altogether six samples were rejected
from the smoker study, zero from the normal dyshemoglobin study and one from
the elevated dyshemoglobin study.
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Figure 40: CO-oximeter scatter plots of hemoglobin fractions in smoker study.
According to literature analysis normal HbMet levels are about 0.5 %. In CO-
oximetry,f RHb readings are calculated as 100 % minus HbO2, HbCO, and HbMet.
This means that errors in other fractions are accumulated in RHb readings. It
is assumed that the mean of different devices is the best alternative to calculate
hemoglobin fractions unless readings cannot be reasoned abnormal. In smoker study,
mean of two IL runs is used. Standard deviations between IL devices are 0.70 %
with HbO2, 0.41 % with HbCO, 0.14 % with HbMet, and 0.59 % with RHb. OSM
was rejected because of abnormally high minimum MetHb levels (range 1.2− 1.8 %,
see Fig 40). From normal dyshemoglobin study mean of two readings with same IL
device were used to be consistent with smoker study even though there was not any
other reason to reject the OSM results. In these two studies, test laboratory was
the same and even if there was nine month gap between the tests devices were the
same. With elevated dyshemoglobin study OSM results were used and ABL results
rejected because of too high minimum HbMet values (1.8 %).
When all data samples are pooled, standard deviation for HbO2 is 0.69 %, for
HbCO 0.32 %, for HbMet 0.20 %, and for RHb 0.61 %. Bias is not taken into
account in this evaluation as it should not affect the results. This is not entirely
true in this case, as the difference in biases between studies introduces some error
in the calibration phase. Standard deviations are used in evaluating the effects of
CO-oximetry reading errors on final results.
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4.2 Development data analysis
During the preprocessing phase the development raw data was analyzed. First
plethymosgraphic data was visually inspected and quality was examined using the
relative amount of hardware adjustments and autocorrelation coefficient signal.
Since the focus was not to concentrate on rejection and handling of artifacts, data
quality analysis was used to compare data from subject to subject and unit to unit.
Then different methods for ratio-of-ratios calculations were compared and the effect
of the reference wavelength was studied for the multi-wavelength system.
Development data quality analysis
During the visual segmentation some problems were inspected in the data. Some-
times signals include artifact at about 2 Hz. This artifact is presented in Figure 41.
Most often it was visible with the thickest fingers, thumb and index. The reason
for the artifact is unclear but it seems that it is present all the time but visible only
when the transmission signal is weak.
Figure 41: Higher frequency noise observed during the visual inspection.
Samples were rejected, when it was not possible to find a good interval around
a blood sample. Subjectwise rejection percentages are listed in Table 12, if the
subject had rejected samples. With subjects 25 and 30 the percentages are high.
Good quality data sequences around the samples were difficult to find in elevated
dyshemoglobin study.
Percentages of good quality data using hardware adjustment and autocorrela-
tion coefficient signals were calculated for each subject and unit. Summary of these
results is presented study-wise in Figure 42. Figure indicates that the amount of
hardware adjustments is small and does not change from study to study. Autocorre-
lation quality is the only parameter that shows differences between studies indicating
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Table 12: Subjectwise rejection percentages from manual data selection, when it
was not possible to find a good interval around a blood sample. Only the subjects
that violated the criteria are listed.
Study Smoker Normal DysHb Elevated DysHb
Subject 3 13 25 26 29 30
No data (%) 3 4 43 3 2 19
that the smoker study executed in April 2009 has the best quality data and that the
quality deteriorates from study to study.
G
o
o
d
d
at
a
p
oi
n
ts
(%
)
HWadjustments Autocorrelation
50
100
Elevated DysHb
Normal DysHb
Smoker
Figure 42: Percentages of good data points with different methods to calculate
quality information.
As plethymosgraphic signal should have good autocorrelation between pulses
autocorrelation coefficient signal was calculated to compare signal quality between
different units. Sensor locations and cushion types of different units are presented
in Table 8. Autocorrelation quality results are presented in Figure 43. Figure shows
that units 3, 5, 6 and 7 show worse results than units 1, 2 and 4. Unitwise hardware
quality analysis showed similar results. Black cushion units and units 3 (pinky) and
4 (thumb) are excluded from the following steps to make sure that good quality data
is used in the development. Pinky showed equally worse results with black cushion
units. Thumb was excluded since it quite different from the other finger and it is
not used in standard pulse oximetry either. Further studies will use the thumb to
discover if it can be used as well.
Ratio-of-ratios calculations
Conventional SpO2 value was calculated using GE pulse oximeter calibration curve
for R660/900 to obtain accuracy information. From this information bias (Eq. 13) and
precision (Eq. 14) were calculated. Because the calibration was not done for this
particular prototype bias was negative with all methods. Results are presented in
Figures 44 and 45. With peak and valley (PV) and delta absorption (dA) methods
2 seconds time window was used. Methods using Fast Fourier Transform, FFT and
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Figure 43: Good quality percentages using autocorrelation coefficient calculation
for different units. Units 1-4 are white cushion units and units 6 and 7 are black
cushion units. Unit 5 was changed to white cushion unit in normal dyshemoglobin
study from subject 3 onwards.
FFTn, were calculated with 128 points. In elevated dyshemoglobin study, standard
deviation of SpO2 is remarkably greater when ratio-of-ratios is calculated with PV
method, which is reasonable as only few points from the data are used in the cal-
culation. Also FFT showed poorer precision and large bias. Based on these results,
dA and FFTn methods were selected to further analysis.
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Figure 44: Precision in SpO2 readings with different methods to calculate ratio-of
ratios.
The length of the interval used in ratio-of-ratios calculations was selected to be
the shortest possible, two seconds with dA method and 128-point FFT (2.56 s). The
selection was confirmed by calculating the precision of SpO2 with longer intervals.
Five and ten seconds interval with dA method and 256- and 512-point FFTs were
used. Results are presented in Table 13. With FFT the SpO2 error due to transfor-
mation resolution should decrease as the length of the FFT increases. No significant
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Figure 45: Bias in SpO2 readings with different methods to calculate ratio-of-ratios.
differences arise in SpO2 precision when the interval is lengthened. This confirmed
that short intervals can be used.
Table 13: SpO2 precision with different interval lengths
Interval length Smoker Normal DysHb Elevated DysHb
(s) dA FFTn dA FFTn dA FFTn
2 1.977 1.991 3.443 3.445 2.052 2.191
5 1.973 1.993 3.435 3.459 2.058 2.199
10 1.967 1.975 3.431 3.437 2.053 2.156
Next the effects of different reference wavelengths were studied. Ratio-of-ratios
were calculated against different reference wavelengths using dA method with two
second window and 128-point FFT calculated from normalized ratios. Methods were
compared by using visually defined good quality data sequences. RSDs of ratio-of
ratios within these sequences for each reference wavelength were calculated. Mean of
RSDs (Eq. 22) is presented in Figure 46. As dA method showed more stable Rs with
all reference wavelengths it was selected to be used in ratio-of-ratios calculations.
The analysis shows also that the noise is greater when 612 nm is used as a reference
wavelength probably due to increased tissue effects with the 612 nm signal. Also
signal balancing was not optimal with 612 nm signal according to the performance
test results with the prototype.
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Figure 46: Mean of RSDs as function of reference wavelength. Ratio-of-ratios are
calculated using dA and FFTn methods.
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Mean of RSDs with reference wavelengths 632 nm and 760 nm using dA method
are presented in Figure 47. The mean of all RSDs was the lowest with these two
wavelengths (Fig. 46). 760 nm (LED 8 in Fig. 17) showed good performance already
in the prototype testing as 632 nm (LED 7 in Fig. 17) was one the worst. The
RSDs are lower nearer the reference wavelengths, which indicates that the noise is
correlated when plethymosgraphic wavelengths are close to each other. The noise is
largest in R612nm/ref .
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Figure 47: RSDs of Rinvivos when 632 nm and 760 nm signals are used as reference
wavelengths.
A typical view of the plethymosgraphic signal from a subject in smoker study
and the calculated ratio-of-ratios is shown in Figure 48. Plethymosgraphic signals
of 612 nm (blue), 660 nm (turquoise), and 800 nm (orange) are presented in top of
each other in the first panel. At the isobestic wavelength of HbO2 and RHb, 800 nm,
plethymosgraphic signal is stable regardless of the HbO2 and RHb fractions. Both
612 nm and 660 nm signals increase, when the saturation falls, because the extinc-
tion coefficient of RHb is larger than the extinction coefficient of HbO2 with 660 nm
and 612 nm (Fig. 16). The change is larger with 660 nm signal. Supersaturation
phase can be seen clearly from the 660 nm signal. Movement artifacts can be seen
in the signals when hands are moved up or down. Ratio-of-ratios calculated with
delta absorption method using 612 nm as reference wavelength are presented in the
second panel and with 800 nmin the third panel. Figure shows that when 612 nm
is used as a reference wavelength the noise is greater in R660nm/ref as expected. In
both cases the noise seems to be random with constant variance. When the hands
are moved the ratio-of-ratios do not change, because they are a measure of blood
composition but after desaturation phase starts ratio-of-ratios become larger as the
transmission with 660 nm signal increases. When 800 nm is used as a reference R
changes from about 0.65 to 1.15. With 612 nm the change is from 0.45 to 0.65.
Unnamed vertical lines in groups of three are blood sample times that are taken
from stable plateaus. This can be seen from the R660nm/800nm signal during the de-
saturation phase. With R660nm/612nm plateaus are mixed with the noise. The lowest
panel shows the hardware adjustment signal.
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Figure 48: A typical view of the plethymosgraphic signals, 612 nm (blue), 660 nm
(turquoise) and 800 nm (orange), and ratio-of-ratios signals, R660nm/612nm and
R660nm/800nm, from a test subject. Vertical lines represent time stamps for differ-
ent phases in the test protocol and unnamed vertical lines in group of threes are
blood sample times.
Development data selection
The amount of noise that the linear inversion solution can handle was studied us-
ing the method presented in Figure 36. First Gaussian RMS noise from zero to
five percent was introduced to all RLBs. Results are presented in Figure 49. Oxyhe-
moglobin, carboxyhemoglobin and reduced hemoglobin fraction specification targets
are violated at noise levels of 2.7, 3.3 and 4.8 %, respectively. Methemoglobin and
reduced hemoglobin accuracy requirements are not violated even with the largest
amount of noise.
As CO-oximetry results are used in calibration of the multi-wavelength system,
their accuracy affects to the results. The error (SD) in CO-oximetry readings is on
average 0.69 % with HbO2. Subject-to-subject variability is estimated to be about
1 % based on the conventional pulse oximetry accuracy. The maximum error caused
by ratio-of-ratios is calculated with Equation 23 to be 1.6 % with oxyhemoglobin if
the accuracy requirement of 2 % is used. This corresponds to about 1.9 % noise in
RLBs according to noise analysis presented in Figure 49.
Figure 48 showed that the noise in Rinvivos seems to be random. Averaging of
random noise reduces the noise with a factor of
√
N , where N is the number of data
points. When the noise in Rinvivos is assumed to transfer directly to the RLBs and
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Figure 49: Effect of Gaussian RMS noise in RLBs to hemoglobin fraction accuracy
with linear inversion solution. Dashed lines represent hemoglobin fraction accuracy
targets: HbO2 and RHb 2%, HbCO 3%, and HbMet 1%.
it is calculated as RSD divided by
√
N a limit for good data can be found. Based
on this analysis data points where RSD/
√
N of any of the Rs is greater than 1.9 %
are rejected.
To find out which wavelength should be used as a reference, RSD/
√
N of ratio-
of-ratios were applied to the system to illustrate the noise. Precisions of hemoglobin
fractions (Eq. 14) were calculated and they are presented in Figure 50. For solving
HbO2 and HbCO, 612 nm is the best reference wavelength although previous analysis
showed that RSDs of Rs (Fig. 46) are greater when 612 nm is used as reference.
With HbMet and RHb the best reference wavelengths were 632 nm and 612 nm,
respectively. Based on these two analysis, 612 nm signal was selected to be used
in further algorithm development, because it was the best reference for all other
hemoglobin species except HbMet.
Rejection percentages using reference wavelength 612 nm are presented in Fig-
ure 51 for each subject. Some problems are present with the subject 11 in the smoker
study and subject 21 in the normal dyshemoglobin study. Visual inspection reveals
that the 2 Hz artifact is present with both of these subjects in the unit 1 (index
finger) and probably affects even with the good intervals. Otherwise the data seems
to be good. In elevated dyshemoglobin study, more than 20 percent of the data
points are rejected with six of the nine subjects, even if the intervals were selected
to be good with visual inspection.
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Figure 50: Standard deviations of hemoglobin fractions when RSDs of Rs are applied
to the system with different reference wavelengths.
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Figure 51: Rejection data percentage with different subjects.
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4.3 Fractional pulse oximetry algorithm
In the algorithm development phase, direct modeling of hemoglobin species was
used as a comparative method. Principal component analysis and forward selec-
tion methods were used to find a regression model for Beer-Lambert ratios. These
methods are evaluated against specifications and with common descriptive statis-
tics used in pulse oximetry. At the end the best algorithm is validated using k-fold
cross-validation.
Forward selection method
Forward selection method was evaluated using F-test and SBIC. Rs were modeled in
four stages with different parameters sets as shown in Figure 35. Table 14 presents
the number of parameters selected in the model. Number of statistically significant
parameters selected with F-test is low regardless from the parameter set. F-test
is only valid is the residuals are normally distributed. Normality was tested with
Kolmogorov-Smirnov test of normality and it revealed that this requirement is vio-
lated. Number of parameters determined through SBIC is remarkably larger.
Table 14: Number of parameters selected in the model using F-test and SBIC as
selection criteria.
Stage 1 model Stage 2 model Stage 3 model Stage 4 model
F-test SBIC F-test SBIC F-test SBIC F-test SBIC
632 nm 5 5 4 10 3 28 3 53
660 nm 0 6 0 6 0 23 0 28
690 nm 1 5 0 10 0 18 0 16
730 nm 1 4 1 17 0 22 0 28
760 nm 1 5 0 14 0 24 0 37
800 nm 2 5 2 11 0 33 0 50
890 nm 3 5 3 8 0 38 0 32
Figure 52 presents the mean square error (MSE) of the regression as a function
of number of parameters included in the model for each ratio. A clear difference
between models is not observable. The MSE for R900nm/612nm is the worst in all
cases and the second worst is R800nm/612nm. The number of parameters used in the
forward selection method is selected with SBIC criteria.
Table 15 lists the first three parameters that were selected in different stages
to the regression model using forward selection method and reference wavelength
612nm. Numbers indicate the wavelengths from the shorter to longer wavelengths:
1 equals 612nm and 8 equals 900nm. In Stage 1 model, R2 and FLT2 are common
parameters. Same parameters or their quadratic or third order terms are often
included in the following stages. This indicates that the shorter wavelengths are
very important for solving the hemoglobin fractions. In Stage 4 model, R8*FLT2 is
the first parameter for longer wavelength RLBs and with shorter wavelength RLBs
only the Rin−vivo is changed to the corresponding Rin−vivo. Because FLT2 is often
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Figure 52: Mean square errors of the regression models from forward selection
method as a function number of parameters.
included in the models, it might mean that the short wavelengths represent the
tissue effects better than the longer wavelengths. In addition, it is beneficial to have
the corresponding or neighbour Rin−vivo in the model.
Table 15: Parameters selected in different stages to the regression model.
RLB Stage 1 Stage 2 Stage 3 Stage 4
2 R2, FLT2, R4 R2, FLT
2
2
, R4 R2,FLT
3
2
, R4 R2*FLT2, R
2
2
, FLT2
3
3 R3, FLT2, FLT3 R3, FLT2, FLT3 R3, FLT2, FLT3 R3*FLT2, R5*FLT3, FLT
2
3
4 FLT2, FLT3, R3 FLT2, FLT3, R3 FLT2, FLT3, R3 R4*FLT2, R4*FLT3, R2*R7
5 FLT2, FLT4, R1 FLT2, FLT4, R
2
2
FLT2, FLT4, R
3
2
R8*FLT2, R8*FLT3,R2*R8
6 FLT2, FLT6, R2 FLT2, FLT6, R2 FLT2, FLT6, R2 R8*FLT2, R7*FLT4, R2*R8
7 R2, R6, FLT2 R
2
2
, FLT2
2
, R6 R
3
2
, FLT3
2
, R6 R8*FLT2, R
2
2
, FLT2
8 R2, R6, FLT2 R
2
3
, R4, FLT
2
2
R2
3
, R4, FLT
3
2
R8*FLT2, R3*FLT7, R2
Hemoglobin species were solved using Beer-Lamber Rs derived from the regres-
sion. From these results percentages that fulfill the requirements specified in Table 6,
bias and precision of hemoglobin fractions were calculated. Comparison of the re-
gression models is based on these figures.
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Principal component analysis
In principal component analysis all terms were included in the regression. Number
of principal components was determined so that 95 percent of the variance would
be explained by the components. Also a scree plot of was drawn as a comparative
method. Scree plot is presented on the left side of Figure 53. On the right side MSE
of the Rs is presented as a function of the number of principal components used in
the regression. Comparing MSEs to the MSEs from the forward selection method
shows that they are worse with PCA. Again MSE for R900nm/612nm is the worst.
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Figure 53: Scree plot of eigenvalues of principal component analysis using reference
wavelength 612nm.
Number of principal components determined with different ways are listed in
Table 16. With reference wavelength 612 nm six PCs accounted for 95 percent of
the variance and nine PCs accounted for 99 percent of the variance. No clear elbow
is seen in the scree plot, but smoother elbow is visible at five PCs. If each princi-
pal component is required to account at least for 0.5 percent of the variance then
nineteen principal components should be used. It was decided to use six principal
components with PCA method.
Table 16: Number of parameters with different order selection methods for PCA.
Method Nbr of PCs
95 % of the variance 6
99 % of the variance 9
Scree plot 5
PC fraction of variance > 0.5% 19
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Algorithm candidate comparison
Few ways were used in evaluating the performance of the algorithms. If normal
distribution of error is assumed, about 68 % of the hemoglobin values should be
within the limits presented in Table 6. For normal distribution, 68 % of the values
lie within one standard deviation (Eq. 14) of the mean. Results with different
algortihms are presented in Figure 54. With all methods but PCA, RHb and HbMet
are in specifications. HbO2 and HbCO are under specifications. In direct modeling,
second-order Taylor polynomes are used to estimate the Jarman’s model for all
hemoglobin fractions.
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Figure 54: Percentage of hemoglobin concentration within specification using differ-
ent modeling algorithms.
In addition, descriptive statistic, bias, precision, and ARMS were calculated and
the results are presented in Table 17. ARMS statistics of SpO2 are also calculated to
be able to compare the algorithm to conventional pulse oximeters that have ARMS
smaller than two percent. ARMS statistics of the algorithms show that they are close
to the accuracy of conventional pulse oximeters. Together these results indicate that
forward selection method with Stage 4 is the best algorithm. Stage 2 model shows
the best results in terms of HbMet precision.
Above statistics do not tell the whole truth of the algorithm performance. Rel-
atively small amount of elevated HbCO and HbMet data points were included the
development data. Values within specifications were calculated separately for high
and low HbCO and HbMet values. HbCO is defined as high if the fraction exceeds
six percents and high HbMet limit is two percents. Figure 55 shows percentage
of dyshemoglobin concentrations within specification using different modeling algo-
rithms. Stage 4 model shows clearly the best results for low HbCO. Low HbMet
levels are well recognized by all algorithms. Stage 4 model shows the best perfor-
mance with high HbMet values but Stage 2 and 3 models are almost as good.
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Table 17: Descriptive statistics of algorithm results
Statistics Method RHb HbO2 HbCO HbMet SpO2
Mean bias (%) Direct HbX -0.04 -0.29 0.31 0.01
Stage 1 model -0.15 -1.30 1.61 -0.16
Stage 2 model -0.06 -0.59 0.69 -0.05
Stage 3 model -0.16 -0.32 0.55 -0.07
Stage 4 model -0.15 -0.17 0.39 -0.08
PCA 0.08 -0.96 1.12 -0.24
Precision (%) Direct HbX 1.61 4.00 4.43 0.84
Stage 1 model 1.60 6.12 6.67 0.93
Stage 2 model 1.71 4.81 5.11 0.62
Stage 3 model 1.73 4.23 4.68 0.71
Stage 4 model 1.39 3.42 3.87 0.72
PCA 3.72 7.60 7.58 1.71
ARMS (%) Direct HbX 1.61 4.01 4.44 0.84 1.67
Stage 1 model 1.61 6.25 6.85 0.94 1.66
Stage 2 model 1.71 4.85 5.15 0.62 1.89
Stage 3 model 1.73 4.24 4.71 0.71 1.83
Stage 4 model 1.40 3.43 3.89 0.73 1.40
PCA 3.72 7.66 7.66 1.72 4.48
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Figure 55: Percentage of dyshemoglobin concentrations within specification using
different modeling algorithms.
Bland-Altman plots were drawn to see how the data points are scattered. Bland-
Altman plot of Stage 4 model is presented in Figure 56. Differently colored data
points in the figure indicate different subjects. Subjects having carboxyhemoglobin
levels from four to ten percents due to smoking are colored with blue. Subjects hav-
ing normal dyshemoglobin levels but changing total hemoglobin values are colored
with red. Subjects that inhaled carbon monoxide are colored with green and subjects
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with nitride infusion are colored black. With visual inspection Stage 4 model showed
the best results in terms of a changing trend seen in HbCO. Carboxyhemoglobin plot
shows that high false elevated carbon monoxide values near zero come mainly from
nitride infusion subjects. Also higher carboxyhemoglobin values indicate falsely low
oxyhemoglobin values as blue and green points are located mainly on the upper part
of oxyhemoglobin plot.
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Figure 56: Bland-Altman plot of result with Stage 4 model. Differently colored data
points indicate different type of subjects, blue points come from smokers, green from
subjects with normal dyshemoglobin level, green from CO inhalation subjects and
black from nitride infusion subjects. Vertical solid line is the mean bias and dashed
lines describe precision of the measurements.
61
Screening tool performance
Statistics calculated in previous section do not describe the algorithm performance
as a dyshemoglobin screening tool. For this purpose confusion matrix counts were
calculated. Threshold for HbCO and HbMet were 6 % and 2 %, respectively. Counts
for data points in each section and total numbers of data points in lower and upper
ranges of confusion limits are listed in Table 18. Number of elevated HbCO data
points is 438 and number of elevated HbMet data points is 91.
Table 18: Values for confusion matrix. FP = False positive, TP = True positive,
TN = True negative and FN = false negative. HbCO threshold is 6% and 2% for
HbMet.
SaO2 FP TP TN FN N neg N pos N total
HbCO 70-100 % 165 290 414 148 579 438 1017
70-90 % 45 83 62 47 107 130 237
90-100 % 120 207 352 101 472 308 780
HbMet 70-100 % 1 70 925 21 926 91 1017
70-90 % 0 2 231 4 231 6 237
90-100 % 1 68 694 17 695 85 780
Figure 57 presents a scatter plot with limits used to recognize elevated HbCO
and HbMet values. A clear trend is visible in methemoglobin but the values are
biased downwards (bias = −0.08 %, precision 0.72 %). Because of the few elevated
HbMet points statistics are highly impacted by lower values. If bias and precision
are calculated from elevated HbMet range bias is −1.4 % and precision is 1.7 %.
Comparing the elevated HbMet bias and precision with the newest study [58] from
Masimo’s SpMet accuracy (bias 0.16 % and precision 0.83 %), the FrOx algorithm
performance is worse. For elevated HbCO bias is −1.9 % and precision 3.2 %. These
values are as good as the values from latest study from Masimo’s SpCO accuracy
(bias 2.99 % and precision 3.27 %) [56].
Based on the values in Table 18 accuracy, sensitivity, and specificity of the al-
gorithm was calculated. Results are presented in Table 19. Data points are also
divided in low and high saturation ranges as literature analysis and previous expe-
rience suggest that the accuracy of pulse oximetry deteriorates as saturation falls.
This is also true in this case. Part of this might be due to biased development data,
there are three times more data points from the high saturation range.
Accuracy of the algorithm in predicting methemoglobin values is good. Elevated
methemoglobin values are well recognized. Specificity of almost 100 % is reached
which is important in medical care where no one wants to have false alarms. Sen-
sitivity for HbMet at low saturation is only 33.3 %, but Table 18 shows that there
are only six blood sample points from the low saturation range for elevated HbMet
values. For carboxyhemoglobin figures are worse. Accuracy of about 60− 70 %
means that three to four cases out of ten are falsely evaluated, which is much for an
effective screening tool.
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Figure 57: Scatter plot of dyshemoglobin concentrations using Stage 4 model. Ver-
tical and horizontal lines describe threshold limits for elevated HbCO (6 %) and
HbMet (2 %). Dashed line is the unity line.
Table 19: Predictive screening performance of algorithm for HbCO and HbMet with
changing saturation range.
SaO2 70-100% SaO2 90-100% SaO2 70-90%
n = 1017 n = 780 n = 237
HbCO HbMet HbCO HbMet HbCO HbMet
Accuracy 69.2 97.8 71.7 97.7 61.2 98.3
Sensitivity 66.2 76.9 67.2 80.0 63.8 33.3
Specificity 71.5 99.9 74.6 99.9 57.9 100.0
Since direct modeling is used as a comparative method, it was studied more
closely. Figure 58 shows that direct modeling of hemoglobin concentrations does
not recognize carboxyhemoglobin at all. Values are scattered around six percent
regardless of the HbCO fraction in the blood. With elevated HbMet levels HbCO
fraction elevates falsely in a similar way as with Stage 4 model. HbMet values are
more evenly positioned on both sides of unity line even with elevated HbMet values
(bias = −0.008 %) but the precision is 2.12 %. Since the amount of elevated MetHb
values was relatively low and the quality in the elevated dyshemoglobin study was
worse than with the other studies, it is possible that these problems can be solved
by collecting more development data with better quality.
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Figure 58: Scatter plot of dyshemoglobin concentrations using direct modeling of
hemoglobin fractions. Vertical and horizontal lines describe threshold limits for
elevated HbCO (6 %) and HbMet (2 %). Dashed line is the unity line.
The effect of noise in in-vivo measured ratio-of-ratios
As the noise was considered to be a problem in the development data, results were
calculated with different amount of noise accepted in the measured in-vivo ratio-of-
ratios. In one data set, all visually selected data points were used, in one data set
RSD/
√
N in any of the in vivo ratio-of-ratios was required to be less than 1.9 %
and in one less than 1 %. Results were run using 5-fold cross-validation (RUN1)
data division. When the noise level requirement is tightened, the amount of data
points decreases from 1280 to 714 and the rejection percentages increase especially
in the elevated dyshemoglobin study. The percentages of hemoglobin values within
specification are presented in Figure 59. Results are better when the noise is reduced
to 1.9 % but deteriotate a bit with HbMet and SpO2 when the RSD/
√
N requirement
is set to 1 %.
Table 20 lists the available data points in elevated dyshemoglobin levels, when
the noise requirement is changed. With the 1 % requirement only 43 elevated MetHb
data points are left for the development, which makes the regression unreliable and
the algorithm performance at high HbMet levels deteriotates.
Table 20: Number of datapoints with different amount of noise is accepted in in-vivo
ratio-of-ratios.
Noise level HbCO HbMet N
low high low high total
All samples 730 547 1117 160 1277
1.9 % 579 438 926 91 1017
1.0 % 410 304 671 43 714
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Figure 59: The effect of noise in Rinvivos to the accuracy of the FrOx algorithm.
Table 21 list the ARMS values for SpO2, HbCO, and HbMet using different noise
levels. Noise reduction enhances the accuracy when 1.9 % criterion is used but
when the noise is further reduced the enhancement is not obvious. With carboxy-
hemoglobin the error increases.
Table 21: ARMS values for SpO2, HbCO, HbMet with different noise levels.
Noise level SpO2 (%) HbCO (%) HbMet (%)
All samples 2.51 4.89 1.33
1.9 % 1.40 3.89 0.73
1.0 % 1.56 4.58 0.57
Figure 60 shows the scatter plot of HbCO fraction with different noise levels.
The trend comes more visible when the noise is reduced but at the same time the
amount of elevated HbCO data points reduces. Scatter plot shows that falsely
elevated HbCO values near zero come mainly from elevated HbMet study.
If subjects with elevated HbMet levels are left out from the algorithm develop-
ment, statistics for HbCO are presented in Table 22. A trend in the HbCO scatter
plot, presented in Figure 61, becomes more visible. With this data set the perfor-
mance of FrOx algorithm exceeds the performance of Masimo’s SpCO measurement
(bias 2.99 % and precision 3.27 %) in the latest study [56]. As a conclusion it seems
that reducing the noise in in vivo ratio-of-ratios improves the algorithm performance.
Table 22: Statistics for HbCO with different noise levels.
Noise level Bias (%) Precision (%) ARMS (%)
All samples 0.26 3.54 3.55
1.9 % 0.04 3.12 3.12
1.0 % 0.01 3.14 3.14
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Figure 60: Scatter plot of carboxyhemoglobin fraction using three different noise
levels. Dashed line is the unity line and solid vertical and horizontal lines represent
the 6 % threshold for elevated HbCO level.
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Figure 61: Scatter plot of carboxyhemoglobin fraction with 1.9 % rejection criterion
when HbMet-subjects are left out from the algorithm development. Dashed line is
the unity line and solid vertical and horizontal lines represent the 6 % threshold for
elevated HbCO level.
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Cross-validation
Until this point algorithms have been compared based on the results that they give.
It seems that Stage 4 model from forward selection method gives the best algorithm.
To get information from the algorithm reliability k -fold cross-validation is run.
Different criterias of division of development data sets can be used in k -fold
cross-validation. Altogether data was collected from 30 subjects and seven units.
As black cushion units and unit attached to left pinky were rejected the amount of
units was reduced to three with 13 subjects and to four with 17 subjects. Data was
partitioned subject-wise into k -fold groups because splitting of individual data files
or unit-wise partitioning would not result in independent data points as development
and validation data points would have come from the same subject.
5-fold, 10-fold, and 30-fold (LOO) cross-validation were calculated. To evaluate
the robustness of the algorithm repeated 5-fold, 10-fold and LOO cross-validation
were done. Since 5-fold cross-validation should show the most deviations it was
run four times and 10-fold and LOO cross-validation were run once. Results are
presented in Figure 62. Results indicate that the algorithm performs similarly re-
gardless of the data point division. Bland-Altman plots were also drawn of each run
and they were consistent with the one presented in previous section (Fig. 56), where
results were calculated using the first division of 5-fold cross-validation.
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Figure 62: Percentage of hemoglobin concentrations within specification with dif-
ferent k-fold data divisions.
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5 Conclusions
The development of the multi-wavelength fractional pulse oximetry algorithm proved
to be challenging. Although the feasibility of the algorithm is not proven, positive
signs were observed and a lot was learned during the research. As assumed, the
measurement of carboxyhemoglobin turned out to be difficult. Methemoglobin mea-
surement showed more promising results but the amount of development data was
not sufficient for regression purposes.
One issue that occurred already in the analysis of the preprocessing results was
that the development data quality was not as good as expected. The quality of the
data from the elevated dyshemoglobin study that covered the elevated carboxyhe-
moglobin and methemoglobin levels, was significantly worse than in the previous
two studies. Used methods to obtain information of the data quality proved to be
good. Autocorrelation coefficient signal showed equal results with the impression
of deteriorating data achieved during the visual inspection. These methods could
be further studied and analyzed to find out how well they recognize abnormalities
in plethymosgraphic signals. Autoregressive moving average models could be one
possible way to reliably recognize abnormalities.
Despite the quality problems, the algorithm showed some promising signs; it
almost reached the accuracy specification requirements. Compared to the commer-
cially available fractional pulse oximetry device, the performance was equivalent or
even better with carboxyhemoglobin and only a bit worse with methemoglobin mea-
surement. Since the regression model uses linear, quadratic, third-order, and cross
terms, it cannot be stated as either simple or robust, yet cross-validation showed
that the results are consistent with different division of development data sets. In
this thesis, part of the error in hemoglobin fractions might arise from the reference
data as they were collected from three different studies and devices. A benefit from
a single study would be that the whole data is developed with the same devices, and
the possible offsets between devices do not disturb the regression modeling.
As there were only three subjects with elevated methemoglobin levels and the
data rejection percentages from these subjects was relative high, the results are not
reliable. A clear trend is seen with methemoglobin but the fraction is underestimated
with the selected Stage 4 model. With direct modeling bias was negligible but the
precision deteriorated. More data is needed to verify the algorithm performance as
a methemoglobin measurement.
Changing the allowed noise level in in-vivo ratio-of-ratios enhanced the perfor-
mance of the algorithm, which strengthens the hypothesis that with better qual-
ity data the feasibility can be proven. With less noisier data, carboxyhemoglobin
showed a clear trend and it fulfilled the accuracy requirement. Even with greater
noise levels, the algorithm reached the accuracy requirements if the subjects from
the elevated methemoglobin study were excluded from the development. Still, it is
difficult to say for sure how the algorithm would behave with better quality data,
because reduction of the noise also reduced the amount of development data.
Noise level was the largest with 612 nm signal, but still it was the best reference
wavelength to be used in the measurement. Also, parameters from the shorter
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wavelengths were favored in the parameter selection. As the prototype development
showed that the signal balancing system is not optimal, especially with shorter
wavelengths, the first step in the future development would be to make improvements
to the prototype device.
Analysis of the effect of reference wavelength showed that the noise level in in vivo
measured ratio-of-ratios grows as the reference wavelength is further away from the
other plethymosgraphic signal. This could be utilized in the algorithm development.
The problem could be split in stages where reduced hemoglobin would be solved first
with the longer wavelengths when carboxyhemoglobin hardly absorbs at all. Better
regression model for the long wavelengths near the reference wavelength could be
developed.
It seems that methemoglobin algorithm can be developed with a sufficient amount
of data. If methemoglobin can be measured reliably, it can be used as an input to the
second part of the algorithm, where rest of the hemoglobin fractions would be solved.
This could solve the problem of many falsely elevated points near zero HbCO level
where the values came simultaneously with elevated methemoglobin levels. Dividing
the problem in parts makes the algorithm even more complex. An effective tool to
determine which path to take is needed, if this approach is applied. Still, dividing
the problem in parts is worth trying in future development of the algorithm.
Altogether the work conducted for this thesis succeeded well and a lot more is
known of the requirements of fractional pulse oximetry measurement. An improved
prototype needs to be developed using the information acquired during the devel-
opment of the first prototype and this thesis. A single study including a sufficient
amount of data from desired dyshemoglobin ranges needs to be collected to prove
the feasibility of the algorithm. Also, the algorithm needs to be simplified and a lot
more work is required before the technology can be commercialized and used as an
effective tool in medical care.
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